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Summary
Resistance of human pathogenic bacteria towards antibiotics is a current and growing threat
to public health. Bacteria have developed a plethora of resistance mechanisms of which the
elimination of the antibiotics from the inside of the cell by active export is one of the most
potent measures.
In facultative pathogenic Gram-negative bacteria, such as Escherichia coli and Pseudomonas
aeruginosa, tripartite eux complexes provide basal resistance against toxic compounds by
lowering the concentration of the antibiotics in the cytoplasm and/or periplasm. These com-
plexes span both the inner and outer membrane and transport antibiotics from the cytoplasm
or periplasm of the cell to the outside medium. The AcrAB-TolC complex from E. coli is the
prototypical example of these export machineries and extrudes not only antibiotics belonging
to dierent classes, but also dyes, bile acids and detergents. The uphill extrusion of antibiotics
out of the cell is driven by the proton-motive force across the inner membrane. Despite that
AcrA and TolC are mandatory for resistance, AcrB is the sole site for energy conversion and
substrate specicity of the entire complex.
AcrB, a member of the three domains of life spanning Resistance Nodulation cell Division
superfamily of transporters, has been intensively characterized by functional and structural
means. Especially high resolution X-ray crystallography structural data provided a wealth of
information. To obtain well diracting crystals, the use of designed ankyrin repeat proteins
(DARPins), which bind specically and in a dened stoichiometry to AcrB, was found to be
benecial.
The functional unit of AcrB is a homotrimer and the monomers adopt three dierent confor-
mations designated loose (L), tight (T) and open (O). It is postulated that the AcrB monomers
cycle consecutively through these three conformational stages in a concerted fashion, from L to
T to O and back to L, much in analogy to the functional rotation observed in the F
1
F
O
-ATP
synthase.
Initial substrate binding occurs in the L monomer, where potential substrate binding sites are
located in the transmembrane domain at the periplasmic side of the inner membrane. Upon
conformational change to the T monomer, a tunnel inside the periplasmic domain leads to
a substrate binding pocket. The binding of drugs to this pocket triggers the proton-motive
force dependent conformational change from the T to the O conformation. Central to the
energization of this process is a proton binding site made out of titratable residues inside
the transmembrane domain of AcrB. Upon proton binding, the free energy is subsequently
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converted into mechanical energy through movements of the transmembrane helices towards
the periplasmic domain, which results in the closure of the entrance tunnel and the binding
pocket initiating substrate release into a newly formed exit tunnel towards TolC. The transient
formation and closure of tunnels inside the periplasmic domain is postulated to resemble the
mechanism of a peristaltic pump.
The focus of this thesis was on the stoichiometric analysis of dierent AcrB/DARPin com-
plexes (Chapter 2), the crystallization of crosslink variants of AcrB (Chapter 3) and initial
experiments to functionally reconstitute AcrB (Chapter 4).
Chapter 2 describes the analysis of DARPin binding to wildtype AcrB and distinct binding
pocket variants of AcrB via densitometry after microchannel electrophoresis, analytical ultra-
centrifugation and via laser-induced liquid bead ion desorption mass spectrometry (LILBID-
MS). Structural analysis of co-crystallized AcrB/DARPins complexes revealed the alternating
DARPin binding stoichiometry of the wildtype AcrB compared to the binding pocket AcrB
variants. Using LILBID-MS, the gradual disassembly of the AcrB trimer and bound DARPin
ligands in dependence on laser intensity was analyzed in solution. At low laser intensity, the
release of the detergent micelle from the AcrB/DARPin complex was observed. By increasing
laser intensity, dimeric and monomeric AcrB species with bound DARPin molecules were de-
tected showing the high anity binding of DARPin to monomeric AcrB species. High laser
intensity LILBID-MS experiments indicated a spectral shift of the monomeric AcrB peak of
3.1 kDa, representing a low molecular weight ligand in all detergent-solubilized AcrB samples
and in the AcrB crystal. The identity of this ligand was further investigated using phos-
pholipid analysis of puried AcrB and AcrB variant samples, and indicated the presence of
phosphatidylethanolamine and possibly cardiolipin, both constituents of the Escherichia coli
membrane.
The structural analysis presented in Chapter 3, describes the introduction of pairs of cys-
teines into a cysteine-free AcrB background resulting in crosslinking and functional impairment
of periplasmic AcrB subdomains and leading to inhibition of the AcrAB-TolC transport activ-
ity. In this study, high resolution crystal structures of four AcrB variants are presented. One
particular cross-linking variant revealed a novel intermediate conformation. This novel con-
formation indicates an independent rearrangement of the subdomains during conformational
change from O to L.
To establish an in vitro transport assay for AcrAB-TolC drug eux, functional reconstitution of
the AcrB trimer was pursued (Chapter 4). Initial experiments demonstrated AcrB association
to liposomes after the reconstitution process and proteoliposomes were shown to stably maintain
5
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a membrane potential. Furthermore, a soluble TolC variant was generated for in vitro complex
formation with reconstituted AcrB and AcrA. This β-barrel-less TolC variant could be produced
in the E. coli cytoplasm and was subsequently puried. Size-exclusion chromatography revealed
the presence of monomeric TolC variant in contrast to the trimeric wildtype TolC.
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Zusammenfassung
Antibiotikaresistenz in humanpathogenen Bakterien stellt eine allgegenwärtige und zunehmende
Gefahr für das Gesundheitswesen dar. Bakterien entwickelten eine Vielzahl von Resistenz-
mechanismen, wobei das Ausschleusen von Antibiotika aus der Zelle durch aktiven Export
eine der bedeutendsten Massnahmen darstellt.
In Gram-negativen Bakterien, wie den opportunistischen Krankheitserregern Escherichia coli
oder Pseudomonas aeruginosa, sind dreiteilige Pumpkomplexe für die grundlegenden Resistenz-
eigenschaften gegen toxische Verbindungen verantwortlich, indem sie deren Konzentration im
Zytoplasma und/oder im Periplasma herabsetzen. Diese Komplexe erstrecken sich über die
innere und äussere Membran und sind in der Lage Antibiotika direkt vom Zytoplasma oder
Periplasma der Zelle nach Aussen zu transportieren. Der Komplex aus AcrA, AcrB und TolC
von E. coli stellt einen Prototyp dieser Exportmaschinerien dar und schleust nicht nur Anti-
biotika verschiedener Klassen, sondern auch Farbstoe, Gallensalze und Detergenzien aus. Der
Transport von Antibiotika gegen den Konzentrationsgradienten wird vom elektrochemischen
Protonengradienten über die innere Membran angetrieben. Obwohl AcrA und TolC für die
Resistenz notwendig sind, ist AcrB allein für die Energieumwandlung und die Substratspezität
des Komplexes verantwortlich.
AcrB, ein Mitglied aus der in allen drei Königreichen des Lebens vertretenen RND (kurz für
engl. Resistance Nodulation cell Division) Transporter-Superfamilie, wurde strukturell und
funktionell detailliert charakterisiert. Vor allem hochauösende Röntgenstrukturanalyse Daten
trugen wertvolle Informationen dazu bei. Der Einsatz von DARPins (kurz für engl. designed
ankyrin repeat proteins), die spezisch und in einer bestimmten Stöchiometrie an AcrB binden,
war ausschlaggebend für die Gewinnung gut streuender Kristalle.
Die funktionstüchtige Einheit von AcrB stellt das Homotrimer dar und die Monomere nehmen
drei verschiedene Konformationen an, die loose (L), tight (T) und open (O) benannt wur-
den. Es ist postuliert, dass die AcrB Monomere, in Analogie zur funktionellen Rotation der
F
1
F
O
-ATPase, aufeinander abgestimmt die Konformationen L, T, O und wieder zurück zu L
durchlaufen.
Erste Substratbindung erfolgt in der L Konformation, in welcher potentielle Substratbindestellen
in der Transmembrandomäne an der periplasmatischen Seite der inneren Membrane vorhanden
sind. Nach der konformationellen Änderung zu T, führt ein Tunnel in der periplasmatischen
Domäne zu einer Substratbindungstasche. Die Bindung von Antibiotika an diese Bindungstasche
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löst die konformationelle Änderung von T zu O aus, die vom elektrochemischen Protonengra-
dienten abhängig ist. Eine Protonenbindestelle aus titrierbaren Seitenketten in der Transmem-
brandomäne von AcrB ist für die Energetisierung dieses Prozesses verantwortlich. Die freie
Energie der Protonenbindung wird in mechanische Energie umgewandelt und durch Positions-
änderungen von Membranhelices in die periplasmatische Domäne weitergeleitet. Dort bewirkt
sie, dass der Eingangstunnel und die Substratbindungstasche kollabieren und das Substrat
durch einen neu entstandenen Ausgangstunnel an TolC weitergeleitet wird. Dieses vorüberge-
hende Entstehen und Verschwinden von Tunnels in der periplasmatischen Domäne ähnelt dem
Mechanismus einer peristaltischen Pumpe.
Der Fokus dieser Arbeit wurde auf die stöchiometrische Analyse von verschiedenen AcrB/
DARPin Komplexen (Kapitel 2), die Kristallisation von Crosslink-Varianten (Kapitel 3)
und erste Versuche AcrB funktionell zu rekonstituieren (Kapitel 4) gelegt.
Kapitel 2 beschreibt die Analyse von DARPin-Bindung zum Wildtyp AcrB und verschie-
denen Substratbindetaschen Varianten von AcrB mit Hilfe von Densitometrie nach Mikrokanal-
Elektrophorese, analytischer Ultrazentrifugation und LILBID (kurz für engl. laser-induced liq-
uid bead ion desorption) Massenspektrometrie. Strukturanalyse von ko-kristallisierten AcrB/
DARPin Komplexen zeigte unterschiedliche Stöchiometrie von DARPins zum Wildtyp und
den Substratbindetaschen Varianten. Mit LILBID-MS wurde der schrittweise Zerfall der AcrB
Trimers und der gebundenen DARPin Liganden in Abhängigkeit von der Laserintensität ana-
lysiert. Bei niedriger Intensität wurde die Ablösung von Detergenzmizellen beobachtet. Bei
steigender Intensität wurden Di- und Monomere AcrB Spezies mit gebundenen DARPins de-
tektiert, die von der hohen Bindungsanität der DARPins für monomeres AcrB zeugen. Hohe
Laserintensitäten verursachten eine Spektralverschiebung im Bereich des monomeren AcrB um
3,1 kDa, wobei es sich um einen niedrigmolekularen Liganden handelt, der in allen Detergenz-
solubilisierten AcrB Proben und in AcrB Kristallen nachgewiesen wurde. Phospholipidanalyse
von gereinigtem AcrB und AcrB Varianten weist auf Bindung von den E. coli Lipiden Phos-
phatidylethanolamin und möglicherweise Cardiolipin an solubilisiertem AcrB hin.
Die Strukturanalyse in Kapitel 3 zeigt das Einfügen von Cysteinpaaren in einer Cystein-freie
Variante von AcrB und die daraus resultierenden Vernetzungen (Crosslinks) und funktionellen
Beeinträchtigungen in den periplasmatischen Unterdomänen von AcrB, die zur Hemmung der
AcrAB-TolC Transportaktivität führen. In dieser Arbeit werden hochauösende Strukturen von
vier Crosslink-Varianten gezeigt. Eine dieser Crosslink-Varianten zeigt eine neuartige Zwischen-
konformation. Diese neue Konformation weist auf eine voneinander unabhängige Reorganisation
der Unterdomänen während der Konformationsänderung von O nach L hin.
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Um einen in vitro Transportassay für AcrAB-TolC bedingten Substrateux zu konzipieren
wurde die funktionelle Rekonstitution des AcrB Trimers verfolgt (Kapitel 4). Erste Experi-
mente belegten, dass AcrB nach dem Rekonstitutionsprozess mit den Liposomen assoziiert und
über die Membran der Proteoliposomen konnte ein stabiles Membranpotential aufgebaut wer-
den. Für die in vitro Komplexbildung von rekonstituiertem AcrB und AcrA wurde eine lösliche
Variante von TolC konstruiert. Diese β-faltblattlose Variante konnte in E. coli produziert und
aus dem Zytoplasma aufgereinigt werden. Grössenausschluss-Chromatographie deutete aller-
dings darauf hin, dass die gereinigte Variante nicht wie im Wildtyp TolC als Trimer, sondern
als Monomer vorlag.
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1 Introduction
1 Introduction
1.1 General introduction
Even diseases have lost their prestige, there aren't so many of them left.
Think it over... no more syphilis, no more clap, no more typhoid...
antibiotics have taken half the tragedy out of medicine.
(Louis Ferdinand Celine, French writer and physician, 1894-1961)
All living organisms are dened by their cellular organization. The cell provides a de-
ned space, separated from the environment by at least one membrane. All cellular
membranes are derivatives of a prototypical design  the unit membrane. Biological
membranes consist of a lipid bilayer, with the aliphatic tails as a core of a hydrophobic
layer, and the hydrophilic headgroups dening the border towards the aqueous phase
on both sides of the membrane (Figure 1.1). This setup eectively prevents transition
of water-soluble substances across the membrane. To have controlled interchange of
substances taken from and expelled to the surrounding environment, cells have mem-
brane embedded proteins. These perform many important tasks like uptake of essential
compounds and expel of noxious substances. Others are involved in signal transduction,
protein or DNA excretion or membrane protein insertion. Extrusion of toxic compounds
has been studied intensively since this phenomenon has been the major culprit in the
ght against cancer and has become alarmingly in the limelight due to antibiotic re-
sistance. The catalysts playing a major role are eux pumps that extrude multiple
antibiotics and anticancer drugs out of the cell. Multidrug eux pumps are often able
to transport a great number of chemically unrelated toxic substances.
Since the discovery of antibiotic drugs at the beginning of the twentieth century, the
treatment of infectious diseases went through dramatic changes. At rst, the availability
of antibiotics was seen as a major triumph of modern science over the perpetual thread
10
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Figure 1.1: Illustration of a dipalmitoylphosphatidylcholine (DPPC) bilayer representing the
structural composition of lipid bilayers in biological membranes. The core of the membrane
consists of the aliphatic tails (here: palmitic fatty acids) and the borders are dened by the
headgroups of the lipids. Water molecules at both sides of the membranes represent the aqueous
composition of the intra- and extracellular uids. In cells, membranes are composed of a set of
dierent lipids (often phospholipids). Colors by element: H white, O red, C gray, P orange, N
blue. (DPPC coordinates from http://moose.bio.ucalgary.ca, dppc128.pdb)
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of infectious microorganisms. In the beginning the antibiotics seemed convincingly eec-
tive against the thread of bacterial borne diseases, however, the mass-application started
to take reverse eects relatively soon. The pressure caused by the widely-used drugs
brought forward strains of bacteria that were less vulnerable towards antibiotic treat-
ment. Due to this antibiotic resistance, infectious diseases that have been kept in check
for decades, are resurgent today. Many diseases that were thought to be eradicated from
developed countries, for example tuberculosis, are newly spreading and resistant strains
set back therapy to the pre-antibiotic era leaving modern medicine with few options to
hold against. Drug resistance in principle can occur in any microbial borne infectious
disease treated with antibiotics. Already nowadays the situation is dramatic, since there
are Gram-negative bacterial strains reported to show resistance towards almost all of
the eective drugs available [1]. Furthermore, many bacteria are able to exchange the
genetic elements causing resistance and share them with pathogens that have never been
confronted with antimicrobial agents. Nowadays the study on resistance mechanisms is
central to understanding the phenomenon of multi-drug resistance. It is hoped for that
in due time, new drugs can be found or alternatively inhibitors of resistance catalysts,
so that the commonly used antibiotic drugs are gaining their potency against bacterial
pathogens.
1.2 Bacterial multidrug resistance pumps
In bacteria, the basis for antibiotic resistance can be associated with four basic mecha-
nisms of resistance [2] (Figure 1.2). Resistant cells can enzymatically inactivate (degrade
or modify) antibiotics to render these nonfunctional (i). The best known example is the
inactivation by hydrolysis of β-lactam antibiotics catalyzed by β-lactamases. Another
strategy is the alteration or modication of the antibiotic target (ii). The introduction
of mutations in e. g. topoisomerase IV or DNA gyrase signicantly reduces the anity
of quinolones and hence decreases the antibiotic eect [3]. Expression of alternative
targets (iii) may give the cell the chance to bypass the inhibitory eect of antibiotics.
The alternative target is not aected by the binding of the antibiotic, but eectively
reduces the free antibiotic concentration, so that the intended target is not encountered.
E. g. in methicillin resistant Staphylococcus aureus (MRSA), an alternative binding pro-
12
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Figure 1.2: Schematic representation of the mechanisms of antibiotic resistance in the bacterial
cell. Antibiotic drugs (blue triangles) may enter the cells over the membrane(s) and be modied
or enzymatically degraded (1). Drug target (hexagon) alteration (2) or alternative drug target
expression (3) may lead to resistance as well. The most potent measure to ght antibiotics is
the reduction of permeability for the bacterial membrane(s) and/or expression of drug eux
pumps. Genetic information encoding for degrading enzymes, altered and alternative targets
and drug eux pumps may be present on plasmids and/or the genome (ring).
tein PBP2a is expressed in addition to penicillin binding protein (PBP). In contrast to
the original PBP, PBP2a is not inhibited by penicillin antibiotics [4]. Preventing accu-
mulation (iv) of the antibiotic drug inside the cell is probably the rst potent measure
to confer resistance to a cell. There is no need to enzymatically alter the drug, or to
modify the target of the drug. Basically, there are two dierent mechanisms to prevent
drug accumulation. The incorporation of drugs is decreased by reduction of perme-
ability through the bacterial membranes. In Gram-negative bacteria, porins allow the
entry of numerous unrelated, water-soluble compounds including antibiotics. The in-
trinsic resistance of Pseudomonas aeruginosa to the hydrophilic β-lactam imipenem,
is correlated to the reduced outer membrane permeability [5]. The other strategy is
actively pumping the drugs out of the cell. The rate of drugs pumped out of the cell
needs to be higher than the rate of entry, to maintain an intracellular sub-toxic con-
centration. Although many of these eux pumps are specic for one drug or a related
group of drugs, there appear to be numerous eux pumps transporting a wide variety
of very dissimilar chemical compounds [6] commonly referred to as multidrug resistance
pumps or multidrug transporters. Inherent to their essential function for every living
cell, multidrug eux pumps are prevalent in all kingdoms of life [7].
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A systematic phylogenetic analysis of solute transporters on basis of the available ge-
nomic data [8] has led to the transport classication (TC) system [9]. This resulted
in a database which provides phylogenetic and associated functional information for
over 500 families of transport proteins. Multidrug resistance pumps have been clas-
sied into ve large superfamilies: the ATP-binding cassette superfamily (ABC), the
major facilitator superfamily (MFS), the drug metabolite transporter (DMT), includ-
ing the small multidrug resistance transporters (SMR), the multidrug/oligosaccharidyl-
lipid/polysaccharide ippase superfamily (MOP), including the multidrug and toxic-
compound extrusion family (MATE), and the resistance nodulation cell division super-
family (RND) [8, 10].
The ABC superfamily
Figure 1.3: Cartoon representation of the ABC -multidrug transporter Sav1866 from Staphy-
lococcus aureus. Sav1866 is a homodimer, where each dimer is comprised of a transmembrane
domain (top, located in the membrane represented by grey bars) and a nucleotide binding
domain (bottom)[11] (pdb ID: 2HYD).
ABC multidrug transporters are primary transporters that couple the substrate trans-
port to ATP hydrolysis. ABC exporters have not only been reported to confer MDR
in bacteria, but also in mammalian cells, fungi and parasites and account for e. g. the
14
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omnipresent cancer cell drug resistance due to the action of P-glycoprotein (ABCB1)
[12] or herbicidal resistance in plants [13]. ABC transporters are comprised of two
trans-membrane domains (TMDs) and two nucleotide binding domains (NBDs). The
NBDs contain several highly conserved motifs such as the Walker A and B motifs that
are responsible for the binding and hydrolysis of ATP. The TMDs, each usually con-
taining ve or six TM helices, span the membranes and facilitate the actual export of
the substrates from the cell.
The domain organization of ABC transporters is dierent in bacteria and eukaryotic
cells. In bacteria, ABC transporters are expressed as half-channels, where one TMD
and one NBD are expressed on a single polypeptide. In contrast, many eukaryotic ABC
transporters are expressed as a single polypeptide chain, carrying all four domains [14].
The best characterized bacterial ABC multidrug transporter is LmrA from Lactococcus
lactis [15, 16]. The only crystal structure available so far from a bacterial ABC eux
pump is that of Sav1866 (Figure 1.3) from Staphylococcus aureus [11, 17]. Recently, the
high resolution structure of mouse P-gp drug eux pump has been elucidated in apo
and drug bound form [18].
Multidrug resistance pumps of the four other superfamilies are secondary antiporters,
energized by the proton (or sodium ion) motive force.
The MF superfamily (MFS)
The MFS contains the largest and most diverse set of transporters, mostly containing
between 12 and 14 trans-membrane helices (TMH) [8]. MFS multidrug transporters are
suggested to function in accordance to the alternating access model, that was postulated
by Jardetzky half a century ago and likewise was proposed for the 12 TMH comprising
E. coli MFS transporters LacY (lactose permease, Figure 1.4) and GlpT (glycerol-3-
phosphate transporter) after their structures were solved [20, 21].
Crystal structure determination revealed a pseudo two-fold organization of two 6 TMH
containing domains duplicated in a single polypeptide [20, 21]. According to the al-
ternating access model, substrate is bound to the membrane spanning transporter,
accessible from one side of the membrane only. In this conformation, an access pathway
15
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Figure 1.4: Cartoon representation of the lactose permease LacY from E. coli. Twelve trans-
membrane helices form a large hydrophilic cavity that is open to the cytoplasmic side [19] (pdb
ID: 2V8N).
is present towards the substrate binding site located at the interior of the membrane
embedded protein. Upon binding of substrate, the transporter changes its conforma-
tion resulting in the exposure of the substrate binding site to the opposite side of the
membrane. In current models an intermediate, `occluded' state is assumed, where the
substrate is trapped in a sluise-type conformation [22]. Most bacterial MFS multidrug
transporters belong to the three Drug/H
+
antiporter (DHA) families. Examples are
Bmr of Bacillus subtilis, QacA and NorA of S. aureus, and EmrD and MdfA from E.
coli [8, 23].
SMR superfamily
The DMT superfamily contains 14 families of transporters with very diverse substrate
specicities in terms of their substrates. Most of these transporters have not been
functionally characterized up to now. Within this family, multidrug transport is only
reported for proteins of the prokaryotic SMR family. SMR transporters consist of 100
140 amino acid long polypeptides comprising four TMH. SMR transporter substrates
are lipophilic or cationic compounds and often quarternary ammonium antibiotics [25,
26].
The best characterized SMR transporter is EmrE of E. coli (Figure 1.5). In vivo and
16
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Figure 1.5: Cartoon representation of the Cα atoms of EmrE from E. coli with the bound
substrate tetraphenylphosphonium (TPP, stick representation) [24] (pdb ID: 3B5D).
in vitro studies have demonstrated that EmrE is functional as a dimer [27]. A major
controversy is the orientation of the monomer within the dimeric assembly [28]. Whereas
evidence for parallel topology has been found with biochemical experiments [29, 30],
there is also evidence for antiparallel topology from structural data [24] and genetic
approaches [31, 32].
The MOP superfamily
Figure 1.6: Cartoon representation of the sodium/substrate antiporter NorM of Vibrio para-
haemolyticus in an outward facing conformation [33] (pdb ID: 3MKT).
The MOP exporter superfamily consists of four families. Most proteins within this group
are predicted to have 12 TMH. Characterized members of the MATE family drive drug
transport on the expense of the electrochemical sodium ion gradient [8, 34]. NorM of
Vibrio parahaemolyticus (Figure 1.6) was the rst multidrug transporter found to utilize
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the sodium ion gradient [35, 36]. Other MATE transporters have been shown to facilitate
Na
+
/substrate antiport as well: VmrA of Vibrio parahaemolyticus and VcmA of Vibrio
cholerae [37, 38]. In E. coli, the NorM homolog YdhE confers resistance to a number
of antibiotics and dyes [39, 40]. Drug eux within the MATE family is, however, not
exclusively coupled to Na
+
ions, as PmpM of P. aeruginosa and AbeM Acinetobacter
baumannii have been shown to facilitate H
+
-coupled drug eux [41, 42].
RND superfamily
Figure 1.7: Cartoon representation of the AcrB homolog MexB from Pseudomonas aeruginosa.
The homotrimeric multidrug pump forms an extrusion complex with MexA and OprM [43] (pdb
ID: 2V50).
The RND superfamily contains a diverse group of transporters. Found ubiquitously in
all phylae of life, RND proteins serve a great number of dierent tasks, one of those
being drug eux. All members of this superfamily share the same overall architecture,
a duplicate of six TMHs with large soluble domains between the rst and second and
seventh and eighth TMH. Functional oligomerization (trimerization) has been observed
in some of the characterized RND transporters and is thought to be a general feature
in its quarterary structural organization. The characterized RND transporters operate
as H
+
or Na
+
/substrate antiporters. Multidrug transport has been shown in two of
the nine families within the RND superfamily so far and inferred for two other families
(Table 1.1). The heavy metal exporter (HME) family is comprised of proteins that
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Table 1.1: Families and example transporters of the RND-superfamily (2.A.6) according to
the Transporter Classication Database (www.tcdb.org).
Family example
The Heavy Metal Exporter CzcA (Ralstonia sp.)
(HME) Family
The Hydrophobe/Amphiphile Eux-1 AcrB (E. coli)
(HAE1) Family (Gram-negative bacteria)
The Putative Nodulation Factor NolG (Rhizobium meliloti)
Exporter (NFE) Family
TheSecDF Family SecDF (E. coli)
The Hydrophobe/Amphiphile Eux-2 MmpL7 (Mycobacterium tuberculosis)
(HAE2) Family (Gram-positive bacteria)
The Eukaryotic Sterol Transporter NPC1 (Homo sapiens)
(EST) Family
The Hydrophobe/Amphiphile Eux-3 gene MJ1562 (Methanococcus jannaschii)
(HAE3) Family (Archeal)
The Brominated, Aryl Polyene Pigment gene ORF4 (Xanthomonas oryzae)
Exporter (APPE) Family
The Dispatched Family Dispatched (Drosophila melanogaster)
are mainly found in Gram-negative bacteria. These provide resistance to toxic divalent
(e. g. Co
2+
, Zn
2+
, Cd
2+
) and monovalent cations (Ag
+
, Cu
+
). CzcA from Ralstonia
sp. confers resistance to copper, zinc and cobalt ions. CzcA forms a complex with
CzcB and CzcC that functions as a H
+
/cation antiporter [44]. Recently, the structure
of CusA, a copper (Cu
+
) and silver (Ag
+
) exporter has recently been elucidated [45].
The homotrimer was crystallized without and with bound copper ions. It was shown
that the binding of copper induces a dierent conformation.
The hydrophobe/amphiphile eux-1 (HAE1) family is largely restricted to Gram-ne-
gative bacteria and most of its members are able to transport a variety of chemically
unrelated compounds [8, 46]. AcrB from E. coli and MexB from P. aeruginosa (Figure
1.7) are considered RND protein paradigms and are structurally as well as function-
ally the best characterized HAE1 transporters. Homologs are known to exist in many
opportunistic and pathogenic bacteria and contribute to their high intrinsic antibiotic
resistance.
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The putative nodulation factor exporter (NFE) family includes only one characterized
example so far. NolG from Rhizobium meliloti, a nitrogen-xing bacterium living in
symbiosis with Medicago sativa, a plant of the family of Fabaceae. Nodulation factors
are extracellular lipooligosaccharid signals that are required to infect the root cells of
the host plants. The nodulation factor export protein may play a role in nodulation of
the host [47].
SecD and SecF are part of the secretory complex in E. coli. They form a heterotrimeric
complex with YajC and are involved in protein translocation [48]. A member of the
HAE2 family is MmpL7 of Mycobacterium tuberculosis. This transporter was shown to
increase resistance against isoniacid, a rst-line antibiotic in tuberculosis therapy [49].
YerP of Bacillus subtilis is the rst RND transporter characterized in Gram-positive
bacteria and was found to confer resistance to surfactin, a strong surfactant [50].
In humans, the NPC1 protein is associated with the distribution of cholesterol in the
cell [51]. It belongs to the eukaryotic sterol transporter (EST) family. There are several
single amino acid substitutions known in this protein that can cause an inactivation of
NPC1, resulting in the accumulation of sterols in lysosomes causing the Niemann-Pick
C1 disease [52].
The hydrophobe/amphiphile eux-3 (HAE3) family contains two hypothetical mem-
brane proteins, MJ1562 and AF1229 from Methanococcus jannaschii and Archaeoglobus
fulgidus, respectively. The function of these proteins is unknown.
The gene ORF4 from the brominated, aryl polyene pigment exporter (APPE) family
codes for a putative membrane protein in Xanthomonas oryzae. It is involved in pigment
export in this plant-pathogen [53].
In Drosophila melanogaster, Dispatched has been found to be required for Hedgehog
(Hh) signaling. The Hedgehog signaling family is crucial for embryonal development in
vertebrates. Dispatched is responsible for the secretion of Hedgehog from the signaling
cells [54]. In the responding cell, the membrane protein Patched (Ptc) is the receptor
for Hedgehog [55]. Interestingly, Hh was reported to be posttranslationally modied
with cholesterol [56] and both, Dispatched and Patched, were shown to contain sterol
sensing domains [57]. Smoothened (Smo), another membrane protein in the Hedgehog
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signaling pathway, was reported to form complexes with Patched [55]. Smoothened
is required for the Hedgehog signal to be mediated into the cell [58, 59]. Chen and
Struhl [59] discussed possible mechanisms of the Smo/Ptc complex. Basically, Patched
is inhibiting Smoothened in the absence of Hedgehog. Upon binding of Hedgehog, the
inhibitory eect of Patched is suspended, resulting in the activation of Smoothened and
causes activation of genes by downstream signaling.
Drug transport complexes in Gram-negative bacteria
The outer membrane of Gram-negative bacteria contributes to intrinsic resistance by
providing an additional barrier (in addition to the inner membrane) to antimicrobial
agents [60]. Consequently, the expelled drug has to cross both membranes in order to
guarantee ecient resistance. Gram-negative bacteria have developed systems to form
complex machineries that span both membranes and the periplasm. These drug ex-
trusion complexes have a tripartite setup comprised by a pump, residing in the inner
membrane (inner membrane protein, IMP), an outer membrane channel (outer mem-
brane factor, OMF) and a membrane fusion protein (MFP) which is essential for com-
plex formation of the IMP, MFP and OMF. The inner membrane eux pump and the
associated MFP are in general encoded by genes located on the same operon, whereas
the OMF is often located elsewhere on the chromosome. In E. coli, the MFP AcrA
and the IMP AcrB are co-localized within the same operon, whereas the OMF TolC is
encoded at a dierent location on the chromosome. Nevertheless, operon-like structures
encoding all three components are also present on the chromosomes of some bacteria
like the cmeABC of Campylobacter jejuni [61] or adeABC of Acinetobacter baumannii
[62]. For some of the IMP it has been shown that they are determinants of substrate
specicity and the main site for energy conversion within the complex. Transporters of
the ABC, MFS and RND superfamilies have been shown to function as IMPs in such
complexes. For example, the E. coli ABC transporter MacB requires the MFP MacA
and the OMF TolC to confer macrolide resistance [63]. In E. coli the MFS transporter
EmrB has been identied to cooperate with the MFP EmrA [64] and suggested to dock
to the OMF TolC [65] as well. Best characterized transmembrane complexes expelling
antibiotics are based on IMPs of the RND superfamily. Complexes based on the HAE1
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pumps AcrB and MexB from E. coli and P. aeruginosa, respectively, are intensively
studied. AcrB recruits the MFP AcrA to form such a complex with TolC. In E. coli
there are several other similar complexes known all of which require the OMF TolC. The
situation is slightly dierent in P. aeruginosa, where there are dierent OMFs available
and have been shown to participate in various tripartite complexes [66]. Tripartite mul-
tidrug eux complexes rely on the presence of all three components. With one of the
components nonfunctional, drug eux activity subsides [67, 68].
The physiological role of tripartite eux systems is still a matter of ongoing research
and speculations [66]. In enterobacteria like E. coli, eux pumps may be evolved to
clear the cell from harmful bile salts present in the natural environment of the animal
gut. Indeed, AcrAB-TolC expels bile salts [69]. However, the natural ability to extrude
a plethora of antibiotic compounds next to bile salts is still puzzling.
1.3 The AcrAB-TolC complex of E. coli, a prototypical multi-drug eux
machinery
1.3.1 AcrB
AcrB from E. coli and MexB from P. aeruginosa are the best characterized RND trans-
porters on both structural [43, 7075] and functional [7680] level. AcrB was rst
described and mapped on the genome of E. coli as acriavin resistance determining
gene B in 1978 [81]. AcrB is the energy module and the substrate specicity determi-
nant within the AcrAB-TolC complex. AcrAB-TolC was shown to confer resistance to
many toxic compounds of various classes of antibiotics, dyes, bile salts, detergents and
organic solvents [82]. Many of the compounds are structurally unrelated and diverse in
size and shape. Moreover, the compounds are neutral, cationic or anionic. A common-
ality of AcrB substrates is their hydrophobicity (pOW
1
greater than -0.3) and limited
size (smaller than 1000 Da).
AcrB comprises of 1049 amino acids and its topology contains a RND signature, i. e. the
structure of AcrB involves twelve transmembrane helices and two large periplasmic loops
1
pOW: Octanol-Water partition coecient
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between TM1 and 2 and TM7 and 8. Due to the duplication in the RND signature
the α-helices 16 and 712 are arranged in a pseudo symmetry within one monomer.
Helices 4 and 10 are located in the center encircled by the other eight helices (Figure
1.8) [70], with TM1 and TM7 at a more peripheral location. The functional unit of
Figure 1.8: Topview on the transmembrane domain of the AcrB trimer. Transmembrane
helices (TM1TM12) of the monomers are arranged around the central cavity (pdb ID: 1IWG).
AcrB is a homotrimer. The rst crystal structure revealed a detailed view on the
overall architecture of the pump (Figure 1.9). The AcrB trimer can be subdivided
into three domains. The (i) transmembrane domain contains twelve transmembrane
helices per monomer and are located in the inner membrane of E. coli cells. The two
periplasmic loops are arranged as large soluble domains protruding into the periplasm.
The membrane proximal part is the (ii) porter domain containing subdomains PN1,
PN2, PC1 and PC2, and the (iii) TolC docking domain with the subdomains DN and
DC is located at the distal end of the trimeric structure. The complex resembles a dome
structure and is about 120Å in total height (Figure 1.9). The monomers are grouped
around a 3-fold symmetry axis perpendicular to the membrane plane. Within the
membrane, the twelve helices of the monomers encircle a central cavity that is assumed
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Figure 1.9: Sideview on the AcrB trimer (pdb ID: 1IWG). The three monomers are shown in
dierent shades of green. The pump can be subdivided into three domains: the transmembrane
domain, the porter domain and the TolC docking domain. The gray bars indicate the inner
membrane of E. coli.
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to be lled with phospholipids in vivo. From the outer leaet of the inner membrane,
the cavity expands into the periplasm and nally tapers into a pore-like structure inside
the porter domain. On top of the periplasmic end of the docking domain, a funnel
can be observed. The rst structural determinations of AcrB showed a symmetrical
trimer, where all three monomers were in a single conformation as implied by the 3-
fold symmetry [70, 72]. Based on the symmetric structure, a transport mechanism was
proposed, where uptake of the substrate was thought to occur from the cytoplasm via
the central cavity. From there the drugs have to pass the central pore to enter the funnel
and subsequently be extruded through the TolC channel to the external medium. Since
the pore consists of three α-helices with close (van der Waals) side chain interaction,
conformational changes were suggested to open and close the pore for substrate transit.
Because of the vertical transport pathway this mechanism was named the elevator
mechanism [22, 71].
Recent crystallographic studies on AcrB revealed another, this time asymmetric, con-
formation of the trimer [7375]. In the crystal, each monomer within the trimer adopts
a dierent conformation. These conformations were postulated to represent three con-
secutive steps of a transport cycle, which were designated loose (L), tight (T) and open
(O). The denotation is in analogy to the conformational states of the F
1
F
O
-ATP syn-
thase as originally proposed by Boyer [83]. The monomers in the initial (symmetric)
crystal structure [70, 72] resemble the L conformation from the asymmetric structures
[7375] with minor deviations. The supposed functional rotation in the transport cycle
of AcrB involves conformational changes of each of the monomers from L to T to O
and back to L again. A series of structural dierences in the conformations can be
observed that aect the organization of the porter domain. The PN1, PN2, PC1 and
PC2 subdomains change their relative position considerably during the anticipated con-
formational cycling. The lateral cleft on the surface of the PC1 and PC2 subdomain
connes a tunnel opening which is about 15Å above the membrane and is leading to the
center of the porter domain. In the T monomer, a conformational shift of the PN2 and
PC2 subdomains causes formation of a second tunnel starting from the transmembrane
domain at the level of the outer leaet of the inner membrane and is merging with the
initial tunnel observed in the loose monomer. Moreover, at the joint of the tunnels in
25
1 Introduction
the T conformation a hydrophobic pocket at the interface of PN2/PC1 becomes ap-
parent. This pocket is lined with a number of hydrophobic residues and is expected
to represent a drug binding pocket. In O conformation, reorganization of the porter
domain (involving PN1, PN2 and PC2 subdomain movements) and part of the trans-
membrane domain result in closure of the lateral cleft. The tunnels disappear and the
binding pocket collapses. An exit pathway comes up, leading from the former binding
pocket to the funnel of the TolC docking domain. Upon conformational change back to
the L conformation, the exit pathway recedes. These ndings inspired the postulation
of pumping transport mechanism by AcrB resembling that of a peristaltic pump. In L
and T conformation, substrates can enter from the periplasm and the membrane via
the tunnels. In the T conformation the binding pocket is able to accommodate enter-
ing substrates. Closing of the lateral tunnels and collapse of the binding pocket in O
conformation squeezes substrates into the newly emerging exit pathway. From there
substrates are translocated via TolC towards to the outside of the cell. The presence of
asymmetric AcrB trimers in vivo and the postulated conformational cycling was con-
rmed by a series of experiments with introduced pairs of cysteines [77, 84]. These
residues were strategically located at the surfaces of subdomains that are involved in
the structural rearrangements during the conformational cycling. In the oxidative en-
vironment of the periplasm, disulde bridges spontaneously formed, covalently locked
the subdomains in a specic conformation and inhibited transport activity of AcrB.
This resulted in signicant reduction of transport of a uorescent substrate in vivo.
Incubation with the reducing agent dithiothreitol (DTT) removed disulde bridges and
restored functionality of AcrB. Furthermore, the functional rotation cycle could be sup-
ported by experiments with covalently (genetically) linked trimers that are expressed
as a single giant protein. Introducing only one non-functional monomer as part of the
covalent trimer basically renders the whole trimeric complex non-functional [80].
In the asymmetric AcrB structure, co-crystallization with 9-bromo-minocyclin and dox-
orubicin was achieved [73].The binding pocket of AcrB is lined with hydrophobic residues,
particular phenylalanine residues, are crucial for substrate binding [73, 78]. Moreover,
substrate binding was only observed in the T conformer of the asymmetric AcrB trimer.
Furthermore, mutational analysis of various phenylalanines in the binding pocket iden-
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tied Phe610 as a key residue in binding of several antibiotic agents. The other phenyl-
alanine residues exhibited a less severe impact on resistance of E. coli cells up on sub-
stitution by alanine [78]. During conformational cycling the binding pocket undergoes
dramatic changes. Only in the T conformation it is forming a hold, voluminous enough
to harbor substrates. The structural conguration and spatial restrictions in L and O
do not allow molecules being bound within this pocket.
In AcrB and the MexB homolog from Pseudomonas aeruginosa four key residues were
identied to be crucial for activity. The titratable residues Asp407, Asp408, Lys940
(Lys939 in MexB) and Arg971, located on transmembrane helices (TM) 4, 10 and 11
respectively, were found to be the functional important residues for proton translocation
and energy/substrate transport coupling [76, 79, 85]. The orientation of these key
residues undergo eective changes in the conformational cycling. Compared to the
situation in the L and T monomer, residues Asp407, Asp408, Lys940 and Arg971 in
the O monomer are reorientated and presumably dier in their protonation state. This
rearrangement, putatively driven by the uptake of (a) proton(s), coincides with a coil
to helix transition in TM8. This appears to be the mechanism of energy transduction,
driven by proton translocation and coupled to the conformational changes in the porter
subdomains, leading to drug extrusion [86].
1.3.2 AcrA
AcrA belongs to the family of membrane fusion proteins (MFPs), a family of auxiliary
adaptor proteins in Gram-negative bacteria, connecting transporters in the inner mem-
brane to channels in the outer membrane. The terminology membrane fusion proteins
stems from the similarity to the membrane fusion protein (F protein) of paramyxovirus,
which is essential for cell penetration and cell fusion [87]. Each adaptor protein func-
tions with a cognate inner membrane transporter. In E. coli, AcrA works in conjunction
with the multidrug eux pump AcrB or the homolog AcrD [88] and the outer membrane
protein TolC [89]. The homologous MFP MexA of P. aeruginosa is part of a very similar
transmembrane complex, which is constituted of the inner membrane pump MexB and
the outer membrane channel OprM. Protein crystallography revealed high resolution
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Figure 1.10: Left panel: organization of AcrA domains on the gene acrA indicated by colored
boxes. Right panel: Cartoon representation of the AcrA homolog MexA crystal structure, with
the structural domains represented in the same representative colors. Hairpin motif (red), lipoyl
domain (blue), β-barrel domain (yellow), membrane proximal (MP) domain (green) (pdb ID:
2V4D).
structures of AcrA [90] and MexA [91, 92] resolved to 2.7 and 2.4 (and 3.0) Å, respec-
tively. AcrA bears an N-terminal signal sequence (amino acid 124), that is cleaved o
after translocation to the periplasm to form the processed protein. At the N-terminus,
a cysteinyl residue (AA 25) is post-translationally palmitylated, concluding the AcrA
maturation. The fatty acid attachment most likely functions as a membrane anchor
and attach AcrA to the inner membrane. The lipoyl anchor seems not to be essential
for its function, since AcrA without lipid modication showed no dierence in function
[93]. Mature AcrA is 373 (25397) amino acids (AA) long. It basically consists of
three globular domains, the β-barrel domain, the lipoyl domain, the membrane proxi-
mal domain and a hairpin α-helical structure (Figure 1.10). Recent revision of crystal
data of MexA revealed a novel dened domain in the area of the disordered terminal
stretches [94]. This membrane proximal (MP) domain has not been observed in crystal
structures of AcrA before. It stretches from the inner membrane into the periplasm and
brings the remaining AcrA domains in range of the TolC docking domain of AcrB. The
following β-barrel domain is composed of six β-sheets and arranges spatial proximity of
the C-terminal disordered domain to the AcrB-TolC docking interface. The C-terminal
domain was found to be essential for the interaction with both AcrB and TolC [95, 96].
The lipoyl domain extends AcrA towards the outer membrane and TolC via a 58Å long
hairpin motif composed of a helix-turn-helix arrangement. The hairpin connects the two
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halves of the lipoyl domain (Figure 1.10). Compared to AcrA, MexA is shorter in both
sequence and structural length. A missing 7 AA repeat in each of the hairpin forming
α-helices is responsible for the shorter overall measure of MexA. The structures of AcrA
and MexA show high structural homology given the 62% identity and 73% similarity
of the adaptor proteins. Nevertheless, they are not able to functionally complement for
each other in the according complexes [97].
1.3.3 TolC
The outer membrane protein TolC of E. coli and homologous proteins (for example
OprM in P. aeruginosa) participate in numerous transport complexes in Gram-negative
bacteria. Best studied example is the AcrAB-TolC multidrug export complex. Being
also part of type I secretion systems, TolC facilitates transport of enzymes and toxins
(e. g. colicin V, hemolysin) and thus is considered to be a major factor for both resis-
tance and pathogenicity. This homotrimeric protein is located in the outer membrane,
and its soluble domain protrudes into the periplasm. Crystal structure of a C-terminally
truncated, but still fully functional TolC is available in high resolution [98]. The three
monomers form a 140Å barrel, comprised of two domains. Anchored in the outer mem-
brane, the β-barrel domain is composed twelve β-sheets arranged in anti-parallel pairs,
where four sheets are donated by each of the three monomers. The periplasmic domain
is a cylindrical barrel formed by coiled coil α-helices. The β-barrel domain and the heli-
cal domain are connected via a short proline-containing hinge-like linkers. The α-helical
domain of around 100Å bridges the periplasm to make contact with the inner mem-
brane pump. Within TolC, short α-helical structures referred to as equatorial domain
pack against the barrel forming helices. N- and C-termini are located in this domain.
Since truncation of 43 C-terminal amino acid residues for this crystallographic study
maintains functional properties of the wild-type, the function of the deleted residues
remains unknown. The structure establishes a tunnel connected to the outside of the
cell with a cavity surrounded by the α-helices. TolC may structurally resemble a tunnel
but the fact that it was crystallized in a closed state it resembles on the functional level
a channel. The periplasmic opening of the outer membrane protein was found to be
obstructed by three of the α-barrel forming α-helices. In a model, Koronakis et al. [98]
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postulate an aperture-like twisting opening-closing mechanism of the inner helices. In a
later study two TolC structures were published showing the channel in a partially open,
asymmetric, state [99]. Furthermore, indications of a putative AcrA-TolC interface in
a groove among the barrel forming α-helices were found [99, 100].
1.4 Trimerization of assembled RND pumps
High resolution X-ray data on RND pumps is available for the prototypical RND pump
AcrB, the HAE1 family homolog MexB from Pseudomonas aeruginosa [43] and CusA
from the HME family [45]. Comparative analysis of predicted topologies revealed a
fundamental structural organization of RND transporters, the RND signature [101].
Remarkably, from the information on the RND pumps up to date, another general
feature appears to be the trimeric state of the functionally assembled transporter com-
plexes. For AcrB, MexB, CusA and MdtBC from E. coli it has been shown that these
proteins form homotrimers, or heterotrimers in the case of the latter. Amino acid se-
quence similarities and identities are shown in detail in Table 1.2. In AcrB, MexB and
Table 1.2: Amino acid sequence similarity and identity values for MdtB, MdtC, AcrB and
CusA.
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MdtB  64.4 43.3 35.9
MdtC 51.6  43.7 36.8
AcrB 27.9 28.1  36.1
CusA 21.7 21.7 20.0 
%
s
i
m
i
l
.
% identity
CusA, the trimeric assembly is observed in the crystal structures. There is no structure
available that shows any of these examples as a monomer. The trimeric organisation
for AcrB, CusA and MdtBC has also been shown using other techniques [80, 102, 103].
The functional rotation hypothesis implies the necessity for oligomers, where conforma-
tional changes in one of the monomers trigger structural rearrangements in a neighboring
monomer. Beside the structural evidence, strong biochemical evidence has been pub-
lished that conrms homotrimeric AcrB as the functional unit [80]. Three genetically
30
1 Introduction
linked monomers, that are encoded and translated from a single open reading frame,
assemble to fully functional pumps. Inactivation of one of the three linked trimers, leads
to the termination of pump activity in the trimeric complex. This nding is in favor of
the functional rotation and substantiates the need of trimers for functionality.
CusA is a member of the RND-heavy metal eux (HME) family in E. coli. It is part of
the CusCFBA complex that confers resistance to copper (Cu
+
) and silver (Ag
+
) ions.
The composition of the functional complex is believed to be comparable to that of the
AcrAB-TolC complex. The inner membrane pump CusA is working in concert with
the MFP CusB and the OMF CusC [87, 104]. CusF, a protein that has been located
in the periplasm and found to bind copper ions may act in concert with the CusABC
metal eux complex [105]. CusA shares 20% identical and 36% similar residues with
AcrB. Comparative analysis by analytical ultracentrifugation of AcrB and CusA in
DDM solubilized solutions revealed the presence of monomeric and oligomeric states
of both proteins. AcrB as well as CusA could be found as mono-, di- and trimers. A
small portion was present in undened oligomeric states bigger than the trimeric forms
[102].
The MdtABC-TolC complex of E. coli has been identied as a multi-drug export ma-
chinery [9, 106]. It confers resistance to cholate and cholate-derivatives, sodium dode-
cylsulphate (SDS) and novobiocin. In this complex, MdtB and MdtC represent RND
proteins belonging to the hydrophobe/amphiphile eux-1 family (HAE1). The eux
complex involves the promiscuous OMF TolC. In correlation to the AcrAB-TolC system,
the MFP MdtA propagates the docking of MtdB
2
C to TolC and stabilizes the periplasm
spanning complex. Substrate specicity for MdtB and MdtC were found to be dier-
ent in minimal inhibitory concentration experiments. MdtC expressed together with
MdtA (in the absence of MdtB) conferred resistance to bile salts, but not to SDS and
novobiocin. These ndings suggest that MdtC is able to form a partial functional trans-
porter MdtC
3
. In contrast, the expression of MdtA and MdtB (in absence of MdtC) did
not confer resistance to either of the reported substrates indicating that MdtB alone
is not able to form a functional pump. Hence both, MdtB and MdtC are required to
form a fully functional transporter, in which MdtB and MdtC seem to be responsible
to confer resistance to SDS and novobiocin and bile salts, respectively [107]. These
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ndings suggest the formation of a heterotrimeric pump composed of MdtB and MdtC,
the stoichiometric constitution of the two components was, however, not clear in the
rst place. Kim et al. described the creation of genetically linked trimers to determine
stoichiometric composition of the RND pump MdtBC [103]. This approach was similar
to the covalently linked trimer experiments of AcrB [80]. It was shown, that a compo-
sition of two MdtB and one MdtC (MtdB
2
C) resembles the wildtype MdtBC activity.
Other combinations of covalently linked MdtB and MdtC exhibit considerably lower or
no activity. Furthermore, the impact of the two proteins in terms of proton transport
on the trimer was investigated. Putative key residues were identied in homology to
Asp407 and Asp408 in AcrB. These putatively H
+
-conducting residues also exist in
MdtB and MdtC. Interestingly, the activity of the complex is diminished upon Asp410
to alanine mutation in any of MdtB, whereas the same mutation in MdtC (Asp401 to
alanine) does only moderately aect activity. Individual functions of MdtB and MdtC
remain unclear, but the experimental data suggest discrete substrate specicities and
unequal participation in energy conversion.
The ability of the RND transporters to form trimers can probably be attributed to the
large periplasmic domains rather than the transmembrane domains. The intermonomer
loop, a structure within the TolC docking domain, is reaching from one monomer to
its neighboring monomer and is supposed to stabilize the trimer [70]. In the DDM
solubilized state, it was shown that the oligomeric state of puried AcrB mutant lacking
the intermonomer loop sequence (∆AA212AA239), is shifted towards the monomeric
state compared to wildtype AcrB (Chapter 2). The corresponding loop sequence of
CusA is shorter than that of AcrB [102] as shown by comparative analysis of the amino-
acid sequence of the loop region of AcrB, CusA, MdtB and MdtC (Figure 1.11).
1.5 Stoichiometry and assembly of the tripartite system AcrAB-TolC
The AcrAB-TolC complex is the major determinant for intrinsic and acquired multidrug
resistance in E. coli. Its components are constitutively expressed in wild type E. coli
cells. This complex is remarkable in its way to transport various drugs from the inner
membrane or the periplasm to the extracellular environment. AcrB, located in the inner
membrane, performs substrate binding and passage to TolC as well as energy coupling
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intermonomer loop
MdtB TSETVRTAITGANVNSAKGSLD......GPSRAVTLSAND 242
MdtC SLDDVRTAVSNANVRKPQGALE......DGTHRWQIQTND 233
AcrB TPVDVITAIKAQNAQVAAGQLGGTPPVKGQQLNASIIAQT 238
CusA SLAEVKSALDASNQEAGGSSIE......LAEAEYMVRASG 235
Konsensus ----V-TA----N-----G-L----------------A--
Figure 1.11: Sequence alignment of the intermonomer loop region of MdtB, MdtC, AcrB and
CusA. Identical residues are shaded blue, gaps are indicated by dots. The alignment was done
using the ClustalW2 program (www.ebi.ac.uk/Tools/clustalw2/index.html).
via the proton motive force. AcrB interacts with TolC via its TolC-docking domain.
TolC provides a gateway for the pump assembly through the outer membrane and to
the outside of the cell. The periplasmic domains of AcrB and TolC protrude into the
periplasm for 70 and 100Å , respectively, which appears sucient to span the periplasm.
AcrA is suggested to connect AcrB to TolC and might function as an adaptor, stabilizing
the complex. Crystal structures of all three individual components are available, but
up to date there is no crystallographic structure of the assembled complex.
The stoichiometry of the AcrAB-TolC complex has been handled very controversially in
literature. From high resolution data, the trimerity of the functional units of the inner
membrane pump AcrB and the outer membrane channel TolC are clear without ambi-
guity. The accurate number of MFPs within the complex could not be determined from
its crystallographic data. The lack of structural data for the entire tripartite complex,
led to several alternative suggestions on the number of the adaptor proteins within the
assembly. Initial data retrieved from AcrA and MexA protein crystals were decient in
structural information of the N- and C-terminal part of the fusion proteins. In litera-
ture this domain was referred to as the disordered domain. This lack of information was
obstructive for understanding the assembly of the tripartite complex, because the ter-
minal domains were thought to be involved in the interaction with the inner membrane
pump. Studies to understand the assembly of the complex involved several biochem-
ical techniques like cross-linking of the individual components, pull-down assays, and
isothermal titration calorimetry. The MexAB-OprM complex of P. aeruginosa showed
tight complex formation, where all three components MexA, MexB and OprM could be
co-puried with tagged MexA, MexB or OprM [108]. In the same study it was shown
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that in a system expressing only two of the three components, neither MexA nor OprM
were co-puried with His-tagged MexB, whereas OprM could be co-puried with His-
tagged MexA. The assembly has also been characterized in cross-link experiments using
dithiobissuccinimidyl propionate (DSP) as cross-linking agent [89, 96, 109, 110] and
isothermal titration calorimetry (ITC) [96]. These experiments provided information
about physical proximity and intersubunit anity of the components in vivo.
In early attempts, the holocomplex was reconstructed based on the crystallographic in-
formation derived from each individual component. However, in one study, crystallized
MexA was described as an helical assembly of thirteen monomers forming a tunnel like
structure [91]. This composition, considered physiologically unlikely and possibly a crys-
tallographic artifact, was not taken into account for complex reconstruction. The idea
of the adaptor proteins laterally covering the binding interface of the inner membrane
pump and the outer membrane channel led to a rst model composed of twelve MexA
proteins wrapping around the periplasmic part of AcrB. The adaptor proteins are not
arranged equiplanar but at dierent distances from the reference point of the outer and
the inner membrane. This model features a 4:1:1 stoichiometry of MexA:MexB:OprM
respectively. Alternatively, a uniplanar model of three dimers of MexA was presented
(2:1:1). Both models suggest molecular interactions in a way, that the adaptor protein's
helical domain contacts the outer rim of the helical tunnel of OprM. In the hexamer
model, the lipoyl- and β-barrel domain of the adaptor make contact with the MexB-
OprM interface and MexB, respectively. Another suggestion emphasizes a sheath of
nine MexA molecules (3:1:1) [92]. This model is similar to the MexA-hexamer congu-
ration in terms of its sites of interaction. Both, the hexamer and the nonamer models
contain a three-fold (pseudo) symmetry which is also true for TolC and AcrB. By using
MexA as a homology model for AcrA (at that time no crystal structure of AcrA was
available), extensive in silico modeling let to yet another interesting trimeric complex
assembly [111]. This construction displays a stoichiometric complex of all three protein
factors (1:1:1). This model derived from competitive analysis from a number of alter-
natively generated models. Furthermore, it also takes the experimentally demonstrated
AcrB and TolC interaction [110] into account for the overall architecture of the tripartite
complex.
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Initial experiments showed that AcrA, AcrB and TolC formed a tripartite complex in E.
coli, similar to that of the toxin exporter HlyBD-TolC [96]. Interactions of all three com-
ponents were demonstrated by chemical cross-linking and co-purication. Using ITC,
it was shown that the pump AcrB and the channel-tunnel TolC exhibit no detectable
interaction but AcrA was able to associate with both AcrB and TolC in the absence of
crosslinking agents [96]. These ndings indicate that AcrB and TolC are either too dis-
tant to one another to be cross-linked in the assembled complex or the anity of these
two proteins is too low to form a complex without the support of the adaptor protein.
In contrast, AcrA seems to bind to AcrB independently of TolC and vice versa. These
ndings conrmed that AcrA is essential for complex formation by contact between
AcrB and TolC. This study and the identication of specic binding sites of AcrA for
TolC and AcrB [95] were basis for successive investigation of the complex assembly.
Direct interactions between AcrA and TolC or AcrB were studied by in vivo cross-
linking and co-purication [92, 100]. Two hetero bifunctional chemical cross-linkers N -
succinimidyl 3-(2-pyridylthio)-propionate (SPDP) and sulfosuccinimidyl 6-[3'(2-pyridyl-
dithio)-propionamido] hexanoate (LC-SPDP) with 6.8Å and 15.6Å spacers, respec-
tively, were used to establish in vivo stable cross-links between accessible lysine side
chains within AcrB or TolC and cysteine residues within AcrA. For that, cysteines had
to be introduced in the naturally cysteine-free AcrA. Due to the distance restraints given
by the chemical cross-linkers, some of the AcrA cysteine-variants allowed cross-linking
with lysines of AcrB or TolC. Moreover, twelve cysteines were introduced in TolC, four
of which showed binding to lysines of the AcrA wild type protein. The cysteines within
TolC were located on the H3, H4, H7 and H8 α-helices, which are involved in AcrA
binding. Vice versa, eight single cysteine AcrA variants were found to cross-link to
wild type TolC [100]. The same approach was used to investigate the interaction of
AcrA and AcrB. Fundamental for the AcrB/AcrA cross-link experiments was the re-
evaluation of crystallographic data of the AcrA homolog MexA [92] as in the light of
the new data a membrane proximal (MP) domain was dened and suggested to play
an important role in interaction between the adaptor protein and AcrB. AcrA residues
in the lipoyl-, β-barrel- and MP-domain were substituted by cysteines for subsequent
use with chemical cross-linkers. Twelve out of 21 cysteines showed cross-link formation
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with wildtype AcrB. In contrast, 16 individual cysteine mutations were introduced in the
periplasmic domain of an otherwise cysteine-less AcrB. In seven single cysteine variants,
cross-linking to wildtype AcrA could be observed in the presence of the two cross-linkers
LC-SPDP and SPDP. Analogous to the AcrA-TolC experiments, the cross-linking data
led to an interaction map of AcrA and AcrB [94]. These two studies presented in vivo
cross-linking assays to map AcrA-TolC and AcrA-AcrB interactions. Docking studies
utilizing the acquired data as distance constraints lead to a detailed experimental based
tripartite AcrAB-TolC model (Figure 1.12). The assembly revealed a stoichiometric
setup and illustrated the eux machinery connecting inner and outer membranes as
a 270Å stretching complex. Notably, all these models integrated the TolC in an open
state conformation and a symmetric AcrB trimer.
This cross-linking method revealed interaction of one of the AcrA α-helices of the hairpin
motif to be involved in the interaction of AcrA and TolC. Several residues located on
the helix α1 were identied in TolC binding, whereas none of the introduced cysteines
in the helix α2 was able to cross-link (Figure 1.13). Considering the distance restraints
from the dierent length of spacers of the cross-linkers, a molecular docking study led
to a single AcrA-TolC model matching the experimental data [94]. This model supports
the interaction of a single AcrA monomer per TolC monomer. The loop of the AcrA
hairpin motif is located just below the equatorial domain of TolC. The α1 helix of
AcrA is embedded in a groove formed by the periplasmic TolC helices H3, H7 and H8.
Coiled-coil interactions seem to be the profound interaction mechanism found in this
association. The AcrA helix extends from the equatorial domain to the periplasmic
opening of the TolC channel in parallel to the TolC helices.
The acquired data from the cross-link experiments was consistent with the former nd-
ings of a 1:1:1 stoichiometry within the complex. In the most recent model [94] one AcrA
monomer binds to one AcrB monomer, in favor for the 1:1:1 complex stoichiometry hy-
pothesis. The lipoyl-domain of AcrA was found to contact the AcrB DN subdomain
of the TolC docking domain. The β-barrel-domain and the MP-domain interact with
the PN2 subdomain. In this way, the AcrA monomer seems to attach to AcrB, snugly
tting to the periplasmic domain. The globular domains of AcrA seem to clamp each
AcrB monomer, forming a lateral bracket stretching from the AcrB-TolC interface to
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Figure 1.12: Schematic illustration of the AcrAB-TolC assembly in E. coli. The RND pump
AcrB (blue, membrane regions gray) is inserted in the inner bacterial membrane (IM). The
outer membrane factor (OMF) TolC (yellow/orange, equatorial domains and membrane regions
gray) resides in the outer membrane (OM) and docks to AcrB in the periplasm. The complex
is stabilized by the membrane fusion protein (MFP) AcrA (green), forming a clamp around
AcrB-TolC interaction site. (This representation is Figure 5A from [94].)
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Figure 1.13: Interaction sites of AcrA and TolC. Eight cysteine residues, introduced to AcrA
helix α1 and the hairpin loop, could be cross-linked to TolC residues using chemical bi-functional
cross-linkers. Likewise, in TolC, four introduced cysteines on helices H3 and H7 could be cross-
linked to AcrA [100]. AcrA wildtype is shown in red. TolC wildtype trimer is shown in grey,
one monomer is highlighted blue. Positions of introduced cysteines are shown as green spheres.
(pdb IDs: 1EK9 and 2F1M).
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the inner membrane.
The latter model ([94], Figure 1.12) envisions a situation in which AcrA clings together
the inner pump AcrB and the outer channel TolC. Interaction between AcrB and TolC,
if any, is very weak and AcrA is necessary for complex formation. This seems to be
in accordance with the necessity for AcrA to have a functional pump. The authors as-
sume that within the complex, binding of AcrA may favor and stabilize the open state
of the TolC channel. Moreover, AcrA may act as a exible connector between AcrB
and TolC, leveraging conformational changes from one protein to the other. Further-
more, the model suggests that binding of inhibitory designed ankyrin repeat proteins
(DARPins) onto AcrB within the tripartite complex is possible. These DARPins bind
to the periplasmic domain and were co-crystallized with AcrB [75]. The attachment
sites of the DARPins were found to be dierent compared to that of AcrA and not over-
lapping (Figure 1.14). This might imply that the inhibitory function of the DARPin is
Figure 1.14: Side view (left) and top view (right) of the asymmetric AcrB with interacting
DARPins (gold) and lipoyl-, β-barrel- and membrane proximal (MP) domains of AcrA (green)
based on the docking model of Symmons et al. [94]. DARPins only bind to the loose (L, blue)
and tight (T, yellow), but not to the open (O, red) conformer of AcrB. There is no sterical clash
between the bound AcrA and DARPin molecules (From Pos with permissions [112]).
based on the inhibition of AcrB itself rather than on the inhibition of the assembly of
the tripartite complex [112]. The complex composition of this assembly and the intrinsic
diculties of purifying and crystallizing membrane proteins render the crystallization
of the entire complex a very delicate matter. The current data-driven model, however,
represents the state-of-the-art archetypal of a multi-protein assembled multi-drug eux
machinery.
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1.6 Cross-linking as technique
High-resolution structures of the asymmetric AcrB revealed three conformational states
in a way that every monomer displays a dierent conformation [7375]. The dierences
between the conformations are most pronounced in the relative location of subdomains
of the periplasmic porter domain and reorganization in the transmembrane domain. Like
snapshots of a continuous movement, the structures provide a basis for the hypothesis
that the three conformations from the crystal structure represent certain states of a
consecutive transport cycle in AcrB. However, crystal structures often display one of
the possible local energy minima and the asymmetric conformation might represent one
of those. To conrm the presence of the dierent conformations in vivo, a cross-link
technique was used that allowed to trace conformational cycling in vivo [77, 84, 113].
In a cysteine-less background (AcrB_cl), numerous variants containing pairs of intro-
duced cysteines were generated. In the oxidative environment of the periplasm, the
sulfhydryl groups (Sγ) of two cysteines residues can form disulde bridges (cross-links).
A general assumption for two Sγ atoms to react to a disulde bond is the proximity
of less than 6.4Å [77]. Furthermore, geometrical restraints of the involved cysteine
residues have to be in favor for the cross-link formation. The proposed cycling of the
monomers through the conformations L, T and O, causes rigid body movements of the
specic subdomains. The rationale of this experiment was that strategically introduced
cysteines located on the surfaces of adjacent subdomains, can form disulde cross-links
when within an appropriate distance of each other. Guided by the high resolution
structure of the asymmetric AcrB crystal, cysteine residues were introduced that would
report the proximity in only one of the conformations L, T or O. Cysteine locations in-
cluded the four subdomains of the periplasmic porter domain (PN1, PN2, PC1, PC2),
the docking domain (DC), the intermonomerical loop (Loop) and transmembrane he-
lices 1 and 7 (TM1, TM7). According to the proposed conformational cycling of the
monomers, formation of cross-links in one of the conformations was anticipated to lock
the involved domains, thus arresting the monomer in a single conformation. Restriction
of one of the monomers was expected to render the trimeric complex nonfunctional.
This study's set of cross-link constructs included mutants that were expected to be
able to form a disulde bridge in either one of the conformations L, T and O. Controls
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that were expected to show cross-links in all or cross-links in none of the conformations
were included as controls. Cross-link variants in this study featured both, intra- and
intermolecular cross-links.
Drug transport capabilities of the cross-link mutants was investigated using conventional
minimal inhibitory concentration (MIC) and uorescence dye (N -phenylnaphthylamine,
NPN) based transport assays with E. coli cells. Additionally, the extent of disulde
cross-linking was quantitatively determined by mass spectrometry. In MIC experi-
ments, AcrB variants containing cysteine pairs causing arrest of the continuous change
of conformations within monomers in general signicantly reduced drug resistance of the
recombinant cells, whereas introduction of single cysteines exhibited negligible or mi-
nor eects on resistance towards various substrates of AcrB. Controls (constructs with
up to 80% cross-links) did not show substantial reduced drug transport. The eect
of cross-linking was further characterized using NPN-uorescence spectrometry. NPN,
administered to de-energized bacterial cells, partitions into the inner membrane. NPN,
an AcrB substrate, shows a strong uorescent signal when located in the hydrophobic
environment of the bacterial inner membrane, whereas removal of this compound after
re-energization of the cells and due to the pumping action of AcrB to the aqueous out-
side of the cell causes a quenching of the signal. The uorescence prole of NPN is a
direct indication of the bacteria's ability to export the drug. Disulde bridge formation
inside AcrB inhibiting the conformational cycling resulted in accumulation of NPN in
the membranes due to diminished transport activity of AcrB. AcrB activity and hence
uorescence quenching could be in part reversed by administration of dithiothreitol
(DTT). Reduction of the disulde bridges within AcrB restored export of NPN and
decreased the uorescence signal.The cross-link experiments support the proposed con-
formational cycling hypothesis derived from high resolution X-ray structures of AcrB.
It elegantly demonstrates the existence of all three conformations (L, T and O) in vivo.
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1.7 Goal of the Thesis
ArcB crystal structures have been obtained by X-ray diraction data up to 2.5Å res-
olution [7375]. The high resolution data not only allow detailed structural insight to
the protein's architecture, but also allow interpretation on the actual transport mech-
anism in which the three observed conformations may represent isolated snapshots of
the complete conformational cycling.
To address this monomer cycling hypothesis, the functional crosslink data [77] was in-
vestigated on a structural level. Double cysteine AcrB variants were crystallized, dirac-
tion data collected and the structures solved. In one case, an intermediate state was
visualized, which provides substantial insights into the cycling events during catalysis.
High resolution data structures of AcrB crosslink variants were obtained as co-crystal
structures with designed ankyrin repeat proteins (DARPins) [75].
With dierent AcrB mutants, we observed dierent AcrB:DARPin stoichiometries. In
this thesis, the stoichiometries of detergent-solubilized AcrB:DARPin complexes were
investigated using LILBID MS, analytical ultracentrifugation, gel ltration chromatog-
raphy and capillary electrophoresis assays.
To establish an in vitro transport assay for AcrAB-TolC drug eux, functional recon-
stitution of the AcrB trimer was pursued. Initial reconstitution experiments in proteoli-
posomes were performed and a soluble TolC variant was generated for in vitro complex
formation with reconstituted AcrB and AcrA.
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2 Manuscript: Analysis of AcrB/DARPin Ligand
Complexes by LILBID MS
This chapter contains a manuscript describing the experiments results and interpreta-
tions of the analysis of AcrB/DARPin complexes.
My contribution to this work was the overexpression purication and crystallization of
the AcrB (wt and AcrB_V612F)/DARPin complexes. Furthermore, I conducted the
capillary electrophoresis and the phospholipid analysis via thin-layer chromatography.
Lucie Sokolova and Mihaela Cernescu performed the LILBID MS experiments.
Dr. Thomas Eicher constructed the AcrB_V612F variant and performed and evalu-
ated the analytical ultracentrifugation experiments with the help of Dr. Christophe
Briand.
Dr. Markus Seeger constructed, overexpressed and puried the AcrB_dl and conducted
the size-exclusion chromatography.
Hi-Jea Cha constructed, overexpressed and puried the AcrB_G616N for the LILBID
MS analysis.
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Analysis of AcrB/DARPin Ligand Complexes by LILBID MS
Lorenz Brandstätter, Lucie Sokolova, Thomas Eicher, Markus A. Seeger, Christophe
Briand, Hi-jea Cha, Mihaela Cernescu, Jürgen Bohnert, Winfried V. Kern, Bernd
Brutschy and Klaas M. Pos
2.1 Abstract
The AcrA/AcrB/TolC complex is responsible for intrinsic multidrug resistance (MDR)
in Escherichia coli. Together with the periplasmic adaptor protein AcrA and the outer
membrane channel TolC, the inner membrane component AcrB forms an eux complex
that spans both the inner and outer membrane and bridges the periplasm of the Gram-
negative cell. Within the entire tripartite complex, homotrimeric AcrB plays a central
role in energy transduction and substrate selection. In vitro selected designed ankyrin
repeat proteins (DARPin) that specically bind to the periplasmic domain of AcrB
were shown to ameliorate diraction resolution of AcrB/DARPin protein co-crystals
[75]. Structural analysis revealed that the specic stoichiometry between trimeric AcrB
wildtype protein to DARPins of 0.5 was shifted to 1 upon interaction of the DARPins
with a V612F and G616N AcrB variant. These specic stoichiometric dierences were
analyzed in solution via densitometry after microchannel electrophoresis, analytical ul-
tracentrifugation and via laser-induced liquid bead ion desorption mass spectrometry
(LILBID MS). Using the latter technology, we investigated the gradual disassembly
of the AcrB trimer and bound DARPin ligands in dependence on laser intensity in
solution. At low laser intensity, the release of the detergent micelle from the AcrB/-
DARPin complex was observed. By increasing laser intensity, dimeric and monomeric
AcrB species with bound DARPin molecules were detected showing the high anity
binding of DARPin to monomeric AcrB species. High laser intensity LILBID MS ex-
periments indicated a spectral shift of the monomeric AcrB peak of 3.1 kDa, represent-
ing a low molecular weight ligand in all detergent-solubilized AcrB samples and in the
AcrB crystal. The identity of this ligand was further investigated using phospholipid
analysis of puried AcrB and AcrB variant samples, and indicated the presence of phos-
phatidylethanolamine and possibly cardiolipin, both constituents of the Escherichia coli
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membrane.
2.2 Introduction
Tripartite complexes are important toxic compound resistance determinants in Gram-
negative bacteria. These complexes are composed of an energy transducing pump,
residing in the inner membrane, a channel in the outer membrane and a periplasmic
adapter protein that establishes a stable connection between the inner-membrane pump
and the outer-membrane channel. In opportunistic pathogens like Escherichia coli and
Pseudomonas aeruginosa, the multidrug resistance (MDR) pumps AcrAB-TolC and
MexAB-OprM, respectively, are responsible for resistance phenotypes against a great
variety of dierent antimicrobial agents. AcrB and MexB represent the inner-membrane
located pump in these complexes and belong to the large superfamily of Resistance
Nodulation and cell Division (RND) transport proteins. These homologous proteins
have been studied in detail on the functional [7679, 86, 114] and structural level [43, 73
75]. AcrA and MexA act as adapter proteins and stabilize binding of AcrB and MexB
to TolC and OprM, respectively [115].
Initial crystallographic data from AcrB protein crystals provided substantial structural
insights and presented the protein as a homotrimer [70], in which all of the monomers
adopt the same conformation. Later, trimerization was postulated to be the physical
basis for a conformational cycling mechanism for drug eux, on basis of recent crystal
structures of asymmetric AcrB, which suggested that each monomer can adopt dierent
conformational states loose (L), tight (T) and open (O) [7375, 86]. Moreover, trimer-
ization was also observed in the crystal structure of the AcrB homolog MexB from P.
aeruginosa [43] and the CusA silver and copper ion RND eux protein [45]. Biochem-
ical experiments with covalently linked AcrB monomers indicated that trimerization of
AcrB is essential for its function and that inactivation of one monomer is sucient to
block the activity of the entire AcrAB-TolC complex [80]. Analytical ultracentrifugation
provided evidence that AcrB is most likely trimeric in its detergent solubilized state as
well [75, 102]. Thus, trimerization is believed a general feature of proteins of the RND
superfamily.
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Designed ankyrin repeat proteins (DARPins) represent a novel antibody-like scaold
that is based on a consensus design of the ankyrin repeat motif [116]. In nature, the
fundamental function of ankyrin repeat proteins is the establishment of specic protein-
protein interactions [117]. Highly specic DARPins have been raised against a number
of target protein using in vitro selection methods such as ribosome display [118] and
phage display [119]. Selected high anity binders have been used in co-crystallization
experiments [120] and with AcrB, the rst example of crystals for a membrane protein
in complex with DARPins was obtained [75]. In the AcrB/DARPin co-crystal struc-
ture, two DARPins are bound to the periplasmic domain of the AcrB trimer. A single
DARPin molecule binds to the surface of the loose (L) and tight (T) conformers each,
but not to the open (O) conformer.
Laser-induced liquid bead ion desorption mass spectrometry (LILBID-MS) is a novel
technique, that allows detection of membrane protein complexes in a detergent-solubilized
state. Depending on the laser intensity, entire protein complexes or contributing sub-
units can be observed [121124]. Here, we analyze three dierent AcrB variants in
detergent-solubilized and crystalline state, with and without bound DARPin molecules.
2.3 Material and Methods
Construction of the AcrB mutants AcrB_dl, AcrB_V612F and AcrB_G616N
AcrB variants (AcrB_dl, AcrB_V612F and AcrB_G616N) were constructed by site-
directed mutagenesis using the Quikchange protocol from Stratagene. In the AcrB_dl
(deleted loop) mutant amino acids 218239 (QLGGTPPVKGQQLNASIIAQTR) were
removed. Amino acid substitution and region deletion were achieved with 5' phospho-
rylated primers. Cloning procedures were performed on the pET24 vector carrying
the wildtype acrB gene as template (pET24acrB
His
, [125]). The nal constructs were
veried by sequencing (Microsynth, Switzerland).
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Drug susceptibility assay
E. coli BW25113 ∆acrB carrying pET24acrB
His
(AcrB wt), pET24acrB_dl
His
(AcrB_dl)
and pET24 (vector) were used for minimal inhibitory concentration (MIC) experiments
as described earlier [77].
Protein expression and purication
Overexpression and membrane preparation of AcrB wt, AcrB_V612F, AcrB_dl and
AcrB_G616N was carried out as previously described [74] with modications. During
solubilization and purication only the detergent n-dodecyl-β-maltoside (DDM, GLY-
CON Biochemicals GmbH, Luckenwalde, Germany) was used throughout the procedure.
Membranes were solubilized in 20 mM Tris/Cl, 150 mM NaCl, 10 mM imidazole, 10%
glycerol and 2% DDM, pH 7.5 (1520 ml total volume). The detergent-solubilized frac-
tion was separated from insoluble material by centrifugation at 145000×g at 4 °C for 1 h
and was subsequently applied to a Ni
2+
-nitrilotriacetic acid (NTA)-agarose column (2 ml
bed volume, Qiagen) pre-equilibrated with 20 column volumes (CV) of buer 1 (20 mM
Tris/Cl, 150 mM NaCl, 10 mM imidazole, 10% glycerol and 0.03% DDM, pH 7.5). The
column was washed with 45 CV buer 1 and subsequently washed with 30 CV buer
2 (20 mM Tris/Cl, 150 mM NaCl, 50 mM imidazole, 10% glycerol and 0.03% DDM,
pH 7.5). AcrB was eluted in 6 ml of buer 3 (20 mM Tris/Cl, 150 mM NaCl, 200 mM im-
idazole, 10% glycerol and 0.03% DDM, pH 7.5). Puried DARPins (inhibitor 1108_19
[75]) were added to the puried AcrB in a two-fold molar excess (to AcrB monomer).
After concentration in centrifugal lter devices with a cuto size of 100 kDa (Amicon Ul-
tra, Millipore), AcrB/DARPin protein mixture (0.7 ml) was subjected to size exclusion
chromatography in buer 4 (20 mM Tris/Cl, 150 mM NaCl, 0.03% DDM, pH 7.5) using
a GE Superdex 200 10/300GL column connected to a GE Healthcare ÄKTAprime sys-
tem. Peak fractions corresponding to AcrB(trimer)/DARPin complexes were collected
and concentrated in centrifugal lter devices with a cuto size of 100 kDa (Amicon
Ultra, Millipore) to 10 mg·ml-1. For the gel ltration run shown in Fig. 2.2, AcrB
and AcrB_dl were puried as above, but with 0.05% cyclohexyl-hexylmaltoside as de-
tergent. Subsequent size-exclusion chromatography was performed using a GE HiLoad
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16/60 Superdex 200 (120 ml pack size) with 10 mM Na-HEPES, pH 7.0, 200 mM
NaCl, and 0.05% cyclohexyl-hexylmaltoside as running buer at 0.4 ml·min-1. Appar-
ent molecular weight values were calculated on basis of a run under identical conditions
with 4 marker proteins (Ferritin (440 kDa), Albumin (67 kDa), Ovalbumin (43 kDa),
Ribonuclease A (13.7 kDa)). Protein concentration was determined using the absorp-
tion at 280 nm (Nanodrop ND-1000 spectrophotometer) or using the colorimetric BCA
protein determination method (Pierce).
LILBID MS
Before subjecting the samples to LILBID MS, a buer exchange on Wizard desalt-
ing columns (Promega) was carried out on puried AcrB wt, AcrB variants and the
AcrB/DARPin complexes into 30 mM NH
4
HCO
3
, pH 7, 0.05% DDM. AcrB/DARPin
co-crystals were dissolved in 20 mM Tris/Cl, pH 7.5 containing 0.05% DDM. Insolu-
ble particles were removed by ltration through a Millex-GV syringe-driven lter unit
(0.22 µm, Millipore). The nal protein concentration was 10 µM with respect to the
AcrB monomer.
Details of the experimental set-up for LILBID have been published previously [126].
Micro-droplets of sample solution (diameter: 50 µm) are produced at 10 Hz by a Piezo-
driven droplet generator and introduced into vacuum via dierential pumping stages.
There the droplets are irradiated one by one by synchronized high-power mid-infrared
laser pulses. These are generated in a home-built optical parametric oscillator using
LiNbO
3
crystals and a neodymium-doped yttrium aluminium garnet; Nd:Y
3
Al
5
O
12
laser as pump. The wavelength of the optical parametric oscillator radiation is tuned
to the absorption maximum of water at around 3 µm corresponding to an excitation of
the stretching vibrations of water. At threshold intensity the droplet explodes resulting
in the emission of ions from liquid into gas phase. There the ions are mass analyzed
in a time-of-ight reectron mass spectrometer. To detect very large biomolecules, a
Daly-type ion detector is used, working up to an m/z range in the low MDa region. At
low laser intensity, LILBID desorbs ions out of the liquid very gently (ultrasoft mode)
enabling detection of the non-covalently assembled protein complexes. At higher laser
intensity (soft mode) the strong interactions are still kept, the weak ones are broken. At
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the highest laser intensities the complex is thermolyzed into its covalent subunits (harsh
mode). The signals from the detector are recorded by a transient recorder. For data
acquisition and analysis a user-written labview program is used. The signal to noise
ratio is improved by subtracting an unstructured background, caused by metastable loss
of water and buer molecules, from the original ion spectra. These dierence spectra
are smoothed by averaging the signal over a pre-set number of channels of the transient
recorder.
Capillary electrophoresis
Protein samples (AcrB wt and AcrB_V612F) co-puried with DARPins via SEC were
analyzed on a 2100 Bioanalyzer (Agilent Technologies Inc.) using the Agilent Protein
230 chips. Samples (approx. 10 mg·ml-1, 4 µl) were prepared according to the manual
with omission of the sample heating step. Relative concentrations of AcrB and DARPin
fractions were calculated from the integrals of the eluted protein peak areas in the
recorded electropherograms by the software 2100 Expert (Agilent Technologies Inc.).
Phospholipid analysis via thin-layer chromatography
Phospholipid analysis of AcrB wt and AcrB_V612F samples was done by thin-layer
chromatography. Reference phospholipids (E. coli polar lipids, 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE), cardiolipin, (Avanti Polar Lipids, Inc.) at
1020 µg in CHCl
3
), DDM solution (1%), buer (20 mM Tris, 150 mM NaCl, 0.03%
DDM, pH 7.5) and puried protein (applied at 5×1 µl steps, 8.5 µg) in buer were
spotted onto a HPTC silica-gel 60 plate (Merck), which was pre-washed by migration
with acetone in a chromatography tank and air-dried in a fume hood for several hours.
The plate was subsequently air-dried and the chromatography step was performed in
a chromatography tank with a mixture of CHCl
3
/MeOH/H
2
O (65:25:4, v/v). Subse-
quently, the plate was dried for 30 min and phospholipids were stained with iodine
(sublimating iodine in a chromatography tank at room temperature). For subsequent
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molybdate staining, the plate was initially heat dried at 160 °C to completely evapo-
rate the iodine and sprayed with molybdatophosphoric acid solution (Carl Roth) with
subsequent development at 160 °C.
Analytical ultracentrifugation
The molecular weight of AcrB wt and AcrB_V612F proteins in complex with bound
DARPins was estimated by sedimentation velocity experiments. 400 µl of puried pro-
tein complexes (in 20 mM Tris/Cl, 150 mM NaCl, 0.03% DDM, pH 7.5) with an OD
280
of 0.7 were applied to an An50-Ti analytical rotor (Beckman Coulter) in a Beckman
Proteome Lab XL-I centrifuge. Buer was used as a reference in sedimentation velocity
experiments. Data were collected at 280 nm. Ultracentrifugation was performed at
40000 rpm at 4 °C. Sedimentation velocities were analyzed with the software SEDFIT
[127].
2.4 Results and Discussion
Oligomeric state of wt AcrB
Crystallographic and biochemical studies provided substantial evidence for the char-
acterized members of the RND superfamily to be functional as a homotrimer [43, 45,
70, 7375, 80, 103]. The state of these proteins in solution has recently been analyzed
by analytical ultracentrifugation [102] and suggests equilibrium between monomeric,
dimeric, trimeric and higher oligomerization states of the AcrB and CusA proteins. We
selected the highly sensitive LILBID MS as method of choice to determine the oligomeric
state of AcrB (theoretical M
W
of His-tagged monomer: 114.6 kDa) in detergent solution
(Fig. 2.1). Under ultrasoft laser condition, the AcrB trimer is observed together with
the detergent micelle as a broad peak ranging from 190 kDa to 260 kDa with a max-
imum at 425 kDa (Fig. 2.1E). With increasing laser intensity, the distribution shifted
to detergent-free trimeric AcrB (apparent M
W
: 355 kDa)(Fig. 2.1B-D). The estimated
detergent micelle from these experiments would be 70 kDa, close to the size of a do-
decylmaltoside detergent micelle in solution [128]. At the highest laser intensity used,
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Figure 2.1: Anion LILBID MS spectra of AcrB
His
in detergent solution. The laser intensity
decreases from the spectrum A (harsh) to the spectrum E (ultrasoft). At harsh laser intensity
(A), the charge distribution of the monomer (blue bars) is detected as the major species in the
spectrum but also a dimeric species (green bar) is observed. At soft laser intensity (B and C),
mainly AcrB trimers (red bars) are observed. At even softer laser intensity conditions (C to
E), the trimeric species is shifting its mass distribution (((AcrB)
3
micelle), grey), most likely
due to the presence of a detergent micelle on the AcrB
His
trimer and displays a peak maxima
corresponding to a charge distribution of a mass of 425 kDa.
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mainly monomeric AcrB (apparent M
W
: 116 kDa) was observed, but still a detectable
amount of di- and possibly trimeric AcrB were present in the sample (Fig. 2.1A).
This extraordinary stability appears to be quite unique compared with other mem-
brane protein complexes tested with LILBID MS [121123]. The AcrB trimer contains
an intermonomeric loop structure, protruding from one monomer to the neighboring
monomer, which might be the determinant for the observed stability of the trimeric
complex. Indeed, deletion of the loop resulted in the formation of mainly monomeric
AcrB (apparent M
W
: 116 kDa compared to calculated M
W
: 114.6 kDa) in detergent
solution (Fig. 2.2) and Escherichia coli harboring the deleted loop gene mutant of
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Figure 2.2: Size-exclusion chromatography elution proles of puried wildtype AcrB (solid
line) and the deleted loop AcrB variant (AcrB_dl, dashed line) on a GE Superdex 200 10/300GL
column coupled to a GE Healthcare ÄKTAprime FPLC system. The main peak of the wildtype
AcrB corresponds to AcrB trimers. In contrast, only a small fraction of AcrB_dl elutes at
comparable elution volume, whereas the majority of the protein sample elutes later, indicating
the presence of AcrB_dl monomers.
AcrB (AcrB_dl) in a ∆acrB background led to an increased sensitivity towards drugs
(Table 2.1). Notably, activity was not reduced completely, indicating that the role of
the loop region could be an exclusive structural one. Since the deleted loop variant
of AcrB is still able to form trimeric assemblies (Fig. 2.2, apparent M
W
: 267 kDa
compared to calculated M
W
: 343.8 kDa), it appears that trimerization is mandatory
for the activity of AcrB, as has been postulated based on biochemical and structural
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Table 2.1: Drug susceptibility of E. coli BW25113 ∆acrB expressing wt and mutant AcrBa
Ery Oxa TPP
+
Novo Cipro
AcrB wt 3264 64 200400 1632 0.0040.008
No AcrB 2 4 6.25 4 0.002
AcrB_dl 4 4 50 8 0.002
a
Abbreviations: Ery=Erythromycin, Oxa=Oxacillin,
TPP
+
=Tetraphenylphosphonium, Novo=Novobiocin,
Cipro=Ciprooxacin, AcrB wt=AcrB wildtype (pET24acrB
His
),
No AcrB=pET24 vector, AcrB_dl=AcrB with deleted loop
(pET24acrB_dl
His
)
data [73, 74, 80, 86].
DARPin binding to AcrB and AcrB variants
AcrB-specic DARPins were selected in vitro using ribosome display, which facilitated
the formation of well-diracting (to 2.5 Å) crystals of AcrB [75]. One AcrB trimer,
containing two bound DARPin molecules, was present in the asymmetric unit. This 3:2
(AcrB monomer to DARPin) ratio was also found in detergent solution using analytical
ultracentrifugation [75].
Initial crystallographic studies of AcrB variants, which have substitutions near the
drug binding pocket located in the porter domain of the periplasmic part of AcrB
(i. e. V612F and G616N), revealed cubic crystal forms (I23) with one AcrB monomer
and one DARPin molecule in the asymmetric unit (Eicher, Cha et al. , unpublished).
A symmetric setup would imply that DARPin/AcrB trimer stoichiometry would have
been shifted from 2 in the case of wildtype AcrB to 3 in the case of the AcrB variants.
To distinguish if the dierent stoichiometries are only observed in crystalline state or
can also be detected in solution, we analyzed the samples using LILBID-MS, capillary
electrophoresis and analytical ultracentrifugation.
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LILBID-MS of AcrB/DARPin complexes
For the AcrB wt/DARPin complex and the V612F/DARPin complex, similar spec-
tra were obtained under high intensity laser conditions (Fig. 2.3) indicating that 2
or more DARPin molecules bind to the AcrB trimer. For the AcrB_G616N variant,
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Figure 2.3: Anion LILBID spectra of AcrB wt, AcrB_V612F variant and AcrB_G616N variant
at harsh laser intensity. The panels A-C display indentical spectra. The bars in the dierent
blue colors (panel A) represent charge distributions of the AcrB monomer with none (dark blue),
one (violet) or two (turquoise) DARPins bound, the bars colored in the green range (panel B)
represent charge distribution of AcrB dimers with none (dark green), one (blue-green) or two
(grey-green) DARPins bound and the bars in the red colored spectrum (panel C) represent
charge distributions of the AcrB trimers with none (dark red), one (red), two (orange) or three
(yellow) DARPins bound.
the AcrB monomer to DARPin stoichiometry was determined to be 3 (Fig. 2.3), indi-
cating a symmetric AcrB:DARPin structural complex commensurate to the threefold
symmetry found in the AcrB_G616N crystals. The spectra of the all three AcrB vari-
ants also revealed a broad peak which might represent an AcrB monomer containing 2
bound DARPin molecules, in contrast to what has been found in the crystal structure
[75]. This observation can be best explained by the formation of DARPin dimers via
a DARPin/DARPin interface and under ultrasoft laser intensities 4 DARPin molecules
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are attached to both the AcrB wt and V612F variant (Fig. 2.4A and B). When using
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Figure 2.4: Anion LILBID spectra of AcrB wt (A) and AcrB_V612F variant (B) at ultrasoft
laser intensity. The bars represent charge distribution of the AcrB trimer with no (brown),
1 (red), 2 (orange), 3 (yellow) or 4 (grey) DARPins bound. In panel B, the inset displays a
magnication of the boxed area.
dissolved AcrB/DARPin crystals (space group P2
1
2
1
2
1
) for measurement with LILBID-
MS (Fig. 2.5), the only stoichiometry which could be detected was the one observed
in the crystal structure i. e. two DARPins bound per AcrB wt trimer. Under ultrasoft
laser intensities, the LILBID MS spectrum of the AcrB masses shifted to higher molec-
ular weight species of 460 kDa, representing the AcrB/DARPin complex of 380 kDa (2
DARPins per AcrB trimer) and a detergent micelle of almost 80 kDa, comparable to
the dierence in molecular weight found in the soluble AcrB preparation (Fig. 2.1).
DARPins stoichiometry from capillary electrophoresis
Complex formation between AcrB wt and AcrB_V612F with DARPin molecules was
analyzed via co-elution using size-exclusion chromatography and further investigation on
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Figure 2.5: Anion LILBID spectra of AcrB/DARPin complex from dissolved orthorhombic
crystals. The laser intensity decreases from the spectrum A (harsh) to the spectrum E (ultra-
soft). The bars colored in the blue range (spectrum B) represent charge distributions of the
AcrB monomer with none or one DARPin bound, the bars in the green range (spectrum B)
represent charge distribution of AcrB dimers with none, one or two DARPins bound and the
red-colored bars (spectra B-D) represent charge distributions of the AcrB trimers with none,
one, or two DARPins bound. The grey bars in spectrum E represent a charge distribution of
the trimer with detergent (micelle), the peak maxima correspond to a mass of 460 kDa.
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AcrB/DARPin stoichiometry of the peak fractions via an Agilent Lab-on-a-Chip cap-
illary electrophoresis system 2100 Bioanalyzer. Electropherograms of AcrB/DARPin
complexes were used for the determination of the concentrations of AcrB and DARPins
by integration of the elution peak areas. Combined data from independent exper-
iments (n=5 and n=6 for AcrB wt and AcrB_V612F, respectively) clearly show a
signicant stoichiometric dierence in DARPin binding between the AcrB wt and the
AcrB_V612F variant, indicating binding of 2 DARPins to the AcrB wt trimer and
binding of 3 DARPins in the case of AcrB_V612F (Fig. 2.6). Whereas this data is in
wt V612F
0
1
2
3
4 *
3 : 2.26
3 : 2.83
D
A
R
P
in
s
 p
e
r 
A
c
rB
 t
ri
m
e
r
Figure 2.6: The molar ratio of DARPins per AcrB trimer (ordinate) is plotted for wildtype
AcrB and AcrB_V612F (indicated on the abscissa). The mean ratios are 2.26 (white bar)
and 2.83 (dotted bar) DARPins per AcrB wt and AcrB_V612F variant, respectively. Errors
(indicated on top of the bars) are calculated as standard error of the mean (SEM). Unpaired
t-test resulted in a P value of 0.022, thus imply a signicant dierence of relative amount of
DARPins bound to AcrB wt and AcrB_V612F.
accordance to the observations in the crystalline assembly of the AcrB wt/DARPins and
AcrB_V612F/DARPin complexes, it deviates from the LILBID measurements where
higher stoichiometries of AcrB/DARPin formations were observed. However, the sam-
ples subjected to capillary electrophoresis where used directly after elution from the
gel ltration column, compared to the samples used for LILBID MS which were sub-
jected to buer exchange and a concentration step, possibly favoring DARPin-DARPin
interaction.
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Analytical UC of AcrB_V612F/DARPin complex
Solubilized AcrB_V612F (trimer fraction after SEC) and AcrB_V612F/DARPin (af-
ter SEC) complexes were subjected to analytical ultracentrifugation and sedimentation
velocity analysis. A distinct sedimentation velocity behavior between AcrB_V612F
with and without DARPins could be observed (Fig. 2.7). The calculated dierence
in molecular weight of AcrB_V612F (373 kDa) and AcrB_V612F/DARPin complex
(427 kDa) could be attributed to the mass of three DARPin molecules (theoretical
molecular weight: 18.3 kDa). The dierence in molecular weight between AcrB wt
without (374 kDa) and DARPins bound complex (408 kDa) was explained by the bind-
ing of two DARPin molecules per AcrB wt trimer [75].
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Figure 2.7: Sedimentation velocity experiments with AcrB_V612F with and without bound
DARPins after SEC. The calculated mass dierence between AcrB_V612F trimers with (dotted
line, 426.6 ± 1.9 kDa) and without DARPins (solid line, 373.1 ± 1.7 kDa) corresponds to the
mass of three DARPin molecules.
Small molecule ligand and phospholipid analysis
The consistent observation of a double peak in all of the LILBID MS spectra taken in
the harsh mode (Fig. 2.3A and 2.5A) representing masses 115.6 kDa and 118.7 kDa
was interpreted as a result of a stripping o (a) small molecule(s) with a (total) mass of
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3.1 kDa from the AcrB monomer. This additional mass was also observed in the spectra
of dissolved AcrB crystals, but has not been observed in the electron density derived
from any of the wildtype or variant AcrB crystal. However, AcrB wt, AcrB_V612F
and their DARPin complexes crystallize in the presence of DDM (M
W
511 Da). In the
AcrB wt/DARPin co-crystal structure, 10 molecules of dodecyl-β-D-maltoside and 1
molecule of dodecyl-α-D-maltoside bound to the trimer are reported [75]. The spectral
shift is observed on the AcrB monomers, suggesting that binding of the molecule(s)
representing this 3.1 kDa mass is much stronger than the already strong binding of the
individual monomers constituting the AcrB trimer. Although a sum of 6 molecules of
DDM per monomer would account for the observed mass, the observed all or nothing
shift of 3.1 kDa mass on the monomer peaks would represent similar anities for all six
DDM molecules to AcrB, which appears unlikely. Moreover, the binding of molecule(s)
representing this spectral shift are clearly distinct from the initial stripping of the de-
tergent micelle, which occurs at very low laser intensities and before the release of AcrB
monomers from the trimeric assembly. The unsatisfactory explanation concerning the
identity of the 3.1 kDa spectral shift triggered the analysis of the presence of phospho-
lipids in our AcrB samples. During the purication process, AcrB is gradually removed
from the bacterial membrane and its hydrophobic domains are integrated into detergen-
t/lipid micelles. Phospholipids originating from bacterial membranes have often been
reported to be co-puried with integral membrane proteins [129, 130].
We initiated thin-layer chromatography (TLC) analysis with puried samples of AcrB
wt and AcrB_V612F to qualitatively identify lipids which might have been co-puried.
A number of phospholipid standards, phospholipid mixtures, DDM solution and sam-
ple buer were run in parallel to the protein samples. The chromatography plates then
were stained by iodine (Fig. 2.8) and molybdatophosphoric acid solution (not shown).
The chromatography pattern of the two protein samples (AcrB wt and AcrB_V612F)
were basically identical (Fig. 2.8, lanes 8 and 9). Two distinct spots are visible that
may represent phospholipids. The signal with the lower retention factor corresponds
with the migration pattern of DDM or cardiolipin, the latter being an E. coli lipid
component. The high retention factor signal observed in the lanes containing pro-
tein samples (Fig. 2.8, lanes 8 and 9) may represent phosphatidylethanolamine (PE),
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commensurate to the samples in lane 1 (polar lipid extract of E. coli) and lane 4
(dioleoyl-phosphatidylethanolamine, DOPE). Considering the mass of each of the po-
tential ligands which could give rise to the signal, several combinations of each of the
detected molecules could explain the spectral shift of 3.1 kDa e. g. 6 molecules of DDM
(M
W
511 Da), or a combination of cardiolipin (1435.9 Da), PE (743.5 Da) and DDM.
The exact combination and ligand identities remain, however, elusive.
Figure 2.8: Identication of phospholipids by thin-layer chromatography (TLC) in puried
AcrB samples. E. coli polar lipids (lane 1), DOPC (lane 2), DOPA (lane 3), DOPE (lane
4), cardiolipin (lane 5), 1% DDM (lane 6), sample buer (lane 7), AcrB wt (lane 8) and
AcrB_V612F (lane9). Samples were dissolved in buers as described in the materials and
methods section. TLC was performed using the eluent system CHCl
3
/MeOH/H
2
O (65:25:4,
v/v). The TLC plates were stained with iodine to visualize the lipid and detergent components.
2.5 Conclusions
We analyzed three dierent AcrB variants in detergent-solubilized and crystalline state,
with and without bound DARPin molecules. The AcrB/DARPin complex stoichiometry
diers depending on the AcrB variant used, consistent with preliminary crystallographic
data on AcrB variant/DARPin co-crystals. Moreover, AcrB trimerization is due to
strong binding of the monomers, most likely via the periplasmic loop (amino acids
218239) protruding from one AcrB monomer into the neighboring monomer. DARPin
binding appears to be even stronger than the interaction between the AcrB monomers,
since interaction of DARPins is observed to trimeric, dimeric and monomeric AcrB. We
also observed the consistent release of a 3.1 kDa mass after high intensity laser exposure,
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which might represent very strong binding of detergent and/or lipids.
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3 Manuscript: Crystal Structures of AcrB Crosslink
Variants
This chapter contains a manuscript describing the experiments, results and interpreta-
tion of the crystallization data from ve dierent crosslink variants of AcrB.
My contribution to this work was the overexpression, purication, crystallization and
collection of crystallographic data of the AcrB variants.
The processing and renement of the data was performed by me with substantial support
by Prof. Dr. Klaas Martinus Pos.
Dr. Markus Seeger did the MALDI-TOF analysis, the MIC and the NPN eux exper-
iment.
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Crystal Structures of AcrB Crosslink Variants
Lorenz Brandstätter, Markus Seeger, François Verrey, Kay Diederichs and Klaas M.
Pos
3.1 Abstract
The AcrA/AcrB/TolC multidrug eux protein complex is the main determinant for
multidrug resistance in Escherichia coli. Within this complex, the inner membrane
component AcrB acts as a proton/substrate antiporter, responsible for substrate speci-
city and energy transduction. In the periplasm, the membrane fusion protein AcrA
promotes the coupling of AcrB to the outer membrane channel/tunnel TolC. Substrates
are exported from the periplasm directly to the outside of the cell. The AcrA/AcrB/-
TolC complex was shown to confer resistance to a great number of structurally dierent
toxic compounds. Whereas rst crystal structures indicated a symmetric state of the
homotrimeric pump component AcrB, latest structures represent asymmetric trimers
where the monomers adopt three dierent conformations. A conformational cycling of
the monomers was proposed as the transport mechanism of AcrB. Recent crosslink ex-
periments were compliant with the presence of all three conformations in vivo. Pairs of
cysteines were introduced into a cysteine-free AcrB background to crosslink and arrest
periplasmic subdomains in particular conformations. It was shown, that crosslinks can
arrest one or more monomers within the AcrB trimer to inhibit transport activity. In
this study, we present crystallization trials and crystal structures of a set of crosslink
variants of AcrB. One particular cross-linking variant revealed a novel intermediate
conformation.
3.2 Introduction
Multiple drug resistance (MDR) in human pathogenic bacteria is nowadays an emerg-
ing and serious thread inside the hospital setting. The cause for MDR phenotypes is
often correlated with the overproduction of drug eux systems. These eux pumps
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represent a potent measure of generating antibiotic resistance by virtue of removing cy-
totoxic compounds from the cell. In the opportunistic Gram-negative human pathogens
Escherichia coli and Pseudomonas aeruginosa, the tripartite eux systems AcrA/Acr-
B/TolC and MexA/MexB/OprM, respectively, have been shown to be responsible for a
majority of multiple drug resistance phenotypes [131].
AcrB is a homotrimeric protein that resides in the inner membrane of the Gram-negative
E. coli and belongs to the Resistance Nodulation and (cell) Division (RND) transporter
superfamily. It forms an assembly with the membrane fusion protein AcrA and the outer
membrane factor TolC. The homotrimeric tunnel/channel TolC is inserted in the outer
membrane protruding into the periplasm, docking onto the docking domain of AcrB.
AcrA binds laterally to the AcrB/TolC docking site, putatively acting as an adaptor
stabilizing the tripartite assembly. The AcrA/AcrB/TolC complex spans the periplasm
and facilitates eux of noxious substances from the inner membrane or the periplasm
directly over the outer membrane to the outside of the cell. Within this complex, AcrB
is the substrate specicity determinant and energy conversion module. Substrates of
the AcrA/AcrB/TolC complex are structurally very diverse [82] and includes various
classes of antibiotics, dyes, detergents and bile salts.
Initial crystal structures of AcrB envisage a trimer, in which every monomer adopts the
same conformation [7072, 125]. More recently obtained crystal structures, however,
showed an asymmetric AcrB trimer [7375]. In these structures, every monomer within
the trimer adopts a dierent conformation. Due to the apparent analogy to the F
1
F
O
-
ATP synthase, the three conformations found in AcrB were designated loose (L), tight
(T) and open (O). The model for AcrB anticipates a conformational cycling of the
monomers, in a way that they sequentially adopt the conformations L, T, O (and L again
to enter a new cycle). Structural rearrangements in the subdomains of the periplasmic
domain of AcrB during conformational cycling establish the basis for a transport process
that resembles the function of a peristaltic pump. In the L monomer, a tunnel leading
from the surface of AcrB (15 Å above the inner membrane) into the periplasmic domain
emerges. This tunnel is prolonged in the T conformation and opens up to a hydrophobic
pocket in the center of the periplasmic domain, the putative substrate binding pocket.
Furthermore, a second tunnel emerges, connecting the AcrB surface within the inner
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membrane to the hydrophobic pocket. These tunnels are hypothetical access routes
for AcrB's substrates to the binding site. In the O conformation, the lateral tunnels
disappear, the hydrophobic pocket collapses and a new passage from the center of the
periplasmic domain leading to the TolC docking domain arises. This tunnel provides
the substrates access to TolC, from where these are expelled to the outside of the cell.
In a following study, we found support for the occurrence of the three conformations in
vivo, by applying cysteine crosslinking [77]. Cysteine pairs were introduced to surfaces
of moving subdomains of a fully functional cysteine free variant of AcrB (AcrB_cl =
AcrB_C493A_C887A) by site-directed mutagenesis. The locations were strategically
selected with regard to the movements of these subdomains in the course of the proposed
conformational cycling. Some of the cysteine variants spontaneously formed crosslinks
in the oxidative environment of the periplasm when the thiol groups came within a criti-
cal range of about 6.4 Å. The rate of crosslinking was quantitatively determined by mass
spectrometry and for any of the three conformations at least one AcrB crosslink variant
was shown to establish a disulde bridge, resulting in the arrest of the drug eux cycling
as indicated by minimal inhibitory concentration assays and N -phenylnaphthylamine
(NPN) eux. In a functional control, pairs of cysteines were introduced at the in-
terface of the intermonomeric loop (Loop) and the TolC docking subdomain DC. This
region appeared invarious between the three conformational states within the asymmet-
ric AcrB structure. In all three conformations, the introduced cysteines are within the
critical range for disulde bridge formation. The extent of cross-linking was determined
to be 80% by MALDI-TOF analysis, but did, however, not signicantly undermine
AcrB activity using minimal inhibitory concentration (MIC) and in vivo NPN eux
experiments.
In this study, we present crystal structures of previously selected crosslink variants [77]
as well as new crosslink variants. The established disulde bridges are visualized in the
crystal structures and give insight into the proposed functional rotation by acquisition
of new conformational states.
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3.3 Results
Here we present the results of crystallization of ve dierent crosslink variants of AcrB.
Throughout this work, the AcrB variants were co-crystallized with DARPin molecules as
described [75] unless indicated otherwise. One of the variants (AcrB_cl_Q229C_E585C,
loop-PC1 subdomain, Table 3.1) resulted in non-diracting microcrystals, whereas dirac-
tion data could be obtained for the other variants: three high resolution datasets (up to
2.3 Å) and one dataset to a resolution of 7.0 Å were obtained (Table 3.1). To compare
the structural deviation of these cross-linked variants with the asymmetric wildtype
AcrB structure, superimposition of the trimers was carried out (Table 3.2).
Table 3.1: Overview of the AcrB variants (derivatives of cysteine less AcrB_cl) used in this
study. Listed are the crystallized crosslink variants, their crosslink rates, space group and
resolution of measured protein crystals.
Q229C_ S562C_ S132C_ S233C_ V225C_
E585C T837C A294C Q726C A777C
subdomains Loop-PC1 PC2-TM7 PN1-PN2 Loop-DC Loop-DC
crosslink rate (%) 40.0
a
15.4
b
41.6
b
17.0
b
80.2
b
space group n.d.
c
P2
1
2
1
2
1
P2
1
2
1
2
1
P2
1
2
1
2
1
I23
resolution (Å) n.d.
c
2.5 2.5 2.3 7.0
gure 3.1 3.3, 3.2 3.4 3.5 -
a
: this work;
b
: from Seeger et al. [77];
c
: crystals did not diract.
AcrB_cl_Q229C_E585C, crosslink between Loop and PC1 subdomain
Based on the high resolution crystal structure of asymmetric AcrB, the distances of
cysteine substitutions at position Q229 and E585 were considered too distant to al-
low disulde bridge formation in any of the three conformations L, T or O (Fig-
ure 3.1, left). Surprisingly, quantication of crosslink formation by matrix assisted
laser desorption ionization-time of ight (MALDI-TOF) revealed a crosslink rate of
about 40%. In minimal inhibitory concentration (MIC) experiments with ve dierent
AcrB substrates, the substitution with one cysteine (E585C in this study, Q229C in
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Table 3.2: Superimposition of the 3D high resolution AcrB variant structures from this study
(24) with wildtype AcrB (1, pdb ID: 2GIF). RMSD (Root Mean Square Deviation) values
of Cα alignment are given in Å. Superimposition was done with structures devoid of ligands
(DARPins, substrates, waters). Superimposition was performed with the program superpose
from the CCP4 program suite [132].
structure 1 2 3 4
AcrB wt (pdb ID: 2GIF) 1 - 1.165 0.928 0.812
PC2-TM7 (S562C_T837C) 2 1.165 - 1.159 1.026
PN1-PN2 (S132C_A294C) 3 0.928 1.159 - 0.483
Loop-DC (S233C_Q726C 4 0.812 1.026 0.483 -
[77]) showed moderate inhibiting eects, whereas the introduction of both of the cys-
teines (Q229C_E585C) signicantly impairs AcrB's drug transport abilities (Table 3.3).
Anity puried Q229C_E585C AcrB displayed a heterogeneous size-exclusion chro-
matography prole indicating high susceptibility towards aggregation with and without
supplemented DARPins. Fractions corresponding to non aggregated AcrB trimers were
collected and used for protein crystallization. Crystallization screens with and without
DARPin binders [75] and in the presence of substrates (minocycline and erythromycin)
resulted in a set of crystals with a cubic habitus under various conditions. Crystals grew
within a two-week period and did not exceed side lengths of 100 µm (Figure 3.1, right).
In X-ray diraction experiments with more than 20 of these crystals, no diraction
could be observed thus far. Initial experiments of several crystal seeding experiments
did not improve size and quality of the crystals.
AcrB_cl_S562C_T837C, crosslink between PC2 subdomain and TM7
The S562C_T837C variant was designed to form a crosslink between the PC2 sub-
domain and TM7 in the O monomer. Only in the O conformation, TM7 approaches
the PN2 subdomain at a distance below the threshold for disulde bridge formation
[77]. Protein crystals could be obtained from the AcrB_cl_S562C_T837C variant
with DARPins and diraction experiments resulted in a high resolution dataset of 2.5
Å. Phases were solved by molecular replacement using a high resolution structure of the
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Figure 3.1: Left: Localization of the engineered disulde bridge in the variant
AcrB_cl_Q229C_E585C (arrow) based on the high resolution model of the AcrB wt (pdb
ID: 2GIF). The cysteine residues are located on the intermonomeric loop and the PC1 subdo-
main (green circle: Loop of the L monomer (blue) and PC1 domain of the T monomer (yellow)).
Right: Non-diracting micro-crystals (20100 µm diameter) of AcrB_cl_Q229C_E585C dis-
playing a cubic habitus could be grown under dierent conditions (Table 3.4). Images of crystals
are displayed at dierent magnications.
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Table 3.3: Minimal inhibitory concentration (MIC) experiments with ve AcrB substrates us-
ing E. coli BW25113∆acrB harboring the empty vector (pET24a) or synthesizing the cysteine-
less AcrB variant AcrB_cl, the single cysteine variants AcrB_cl_E585C and AcrB_cl_Q229C,
the crosslink variant AcrB_cl_Q229C_E585C or the negative control AcrB_D407N_D408N.
MIC (µg·ml-1)
constructs TPP
+
R6G Berberine Erythromycin Oxacillin
pET24a 12.5 4 64 <2 4
acrB_cl 800 128 1024 64 128
D407N_D408N n.d. 8
a
64 <2 <4
Q229C
b
400 128 1024 64 128
E585C 400 128 1024 64 128
Q229C_E585C 200 16 512 16 16
abbreviations: MIC, minimal inhibitory concentration; pET24, empty
vector; acrB_cl, cysteine less acrB; D407N_D408N, non-functional
acrB; E585C, acrb_E585C; Q229C_E585C, acrb_Q229C_E585C;
TPP
+
, tetraphenylphosphonium; R6G, rhodamine 6G; n.d. not deter-
mined
a
: Thomas Eicher, Thesis;
b
: Seeger et al. [77]
wildtype AcrB (Eicher, PhD thesis). In the acquired structural model of this crosslink
variant, two of the monomers closely resemble the monomers in T and O conformation
in the asymmetric wildtype AcrB [74]. In the O conformation, electron densities provide
indication for partial crosslinking, revealing densities for crosslinked as well as reduced
cysteines (Figure 3.2). The two reduced cysteines (blue) are represented as sticks and
their 2Fo-Fc electron density is drawn at 1σ as a blue mesh. Clearly, electron density
supported the existence of non-linked cysteines pointing with suboptimal geometries for
cysteine-disulde bridge formation. Additionally, dierence (Fo-Fc) electron densities
(green mesh) at 3σ indicate the presence of covalently linked cysteine residues (green
sticks) in an alternative conformation. The global conformation of the O monomer
appears not to be aected by the absence or presence of the disulde crosslink.
The third monomer within the AcrB_S562C_T837C has a similar conformation as
observed in the L monomer of the AcrB wildtype structure. However, electron density
is clearly supportive of crosslinking within this monomer and apparently inuences the
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Figure 3.2: Close-up view of the PC2-TM7 interface of the O monomer of the AcrB crosslink
variant S562C-T837C. The introduced cysteines residues are shown in stick representation.
The corresponding electron density (2Fo-Fc) at 2.5Å resolution is pictured as blue mesh (at
1σ). Dierence electron densities (Fo-Fc) (at 3σ) in green are indicative of an alternative
conformation and partial crosslink of the cysteines in the O monomer.
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conformational state of PC2 subdomain within the porter domain. (Figure 3.3).
Figure 3.3: Superimposition of AcrB_cl_S562C_T837C (cartoon representation; L, blue;
T, yellow; O, red) on the asymmetric wildtype AcrB (pdb ID: 2GIF; light colors). Disulde
bridges (stick representation in green, encircled) can be observed in the L (blue) and O (red)
monomers: the L and the O conformer. Co-crystallized DARPin molecules are omitted for
clarity. Inset: Superimposition of the L monomer of the wildtype AcrB (pdb ID: 2GIF; light
blue) and crosslink variant S562C_T837C (blue) in the PC2 subdomain and TM7 region.
Disulde bridges of the variant are shown in green (stick representation). The crosslink clearly
aects the conformation of the PC2 subdomain in the L monomer of the crosslink variant and
reveals substantial deviation compared to the wildtype L monomer conformation. Other porter
subdomains are omitted for clarity.
AcrB_cl_S132C_A294C, crosslink between PN1 and PN2 subdomains
The AcrB_cl_S132C_A294C was shown to form a disulde bridge between the PN1
and the PN2 subdomain in the L monomer (at a quantity of about 41% crosslinking)
[77]. This variant was co-crystallized with DARPin binders and a dataset to a reso-
lution of 2.5 Å has been obtained. The space group was determined P2
1
2
1
2
1
and cell
parameters were found 148.27 Å, 162.98 Å and 248.05 Å for a, b and c. The phase
problem was solved by molecular replacement with a high resolution model of the wild-
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Figure 3.4: Superimposition of the porter domains of AcrB_cl_S132C_A294C (blue: L,
yellow: T, red: O monomer) and the asymmetric structure of wildtype AcrB (pdb ID: 2GIF;
light colors). A disulde bridge could not be observed in the structure. In the L monomer,
where crosslinking of the cysteines (green, stick representation) was anticipated, the distance
between the Sγ atoms of C132 and C294 was 7.64 Å, which is suboptimal to support disulde
bridge formation.
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type AcrB (Eicher, PhD thesis). Electron densities derived from the structure factors
of the S132_A294C variant were not indicative of disulde bridges. In the L monomer,
the distance between the sulfhydryl groups of the cysteine residues (Sγ) was 7.64 Å,
a distance too long for crosslinks to be established and deviating from the original es-
timations by in silico mutagenesis (Figure 3.4). However, a crosslinking percentage of
41% was observed by Seeger et al. [77] in membrane localized AcrB_cl_S132C_A294C
by MALDI-TOF analysis. It appeares, therefore, that the population of cross-linked
variants might not have been incorporated into crystals.
The structure of AcrB_cl_S132C_A294C (PN1-PN2 cross-link variant) was superim-
posed onto the asymmetric structure of the wildtype AcrB (pdb ID: 2GIF) consider-
ing the backbone atoms of both structures. The RMSD of the superimposition was
found 0.928 Å (Cα atoms). Hence, only minor deviations between the structure of
AcrB_cl_S132C_A294C and the wildtype are apparent.
AcrB_cl_S233C_Q726C, a crosslink variant with disulde bridge between Loop
and DC subdomain
AcrB_cl_S233C_Q726C (Loop-DC cross-link variant, Figure 3.5) was constructed with
the expectation to form crosslinks in all three monomers. The distances between the
sulfhydryl groups in the introduced cysteine residues varied from 5.2 to 6.3 Å, as re-
ferred from the high resolution data of wildtype AcrB [77]. The amount of cross-link
was determined to be 17% [77]. In the N -phenylnaphthylamine (NPN) eux assay
(Figure 3.5, inset), this variant showed a slightly aected transport activity compared
to AcrB_cl (as a positive control). Addition of DTT, resulting in the reduction of the
disulde bridges, had almost no eect on the NPN eux. MIC determination by Seeger
et al. [77] demonstrated that the drug transport activity of this variant corresponds
to that of the control (AcrB_cl). AcrB_cl_S233C_Q726C was co-crystallized with
DARPins and the AcrB substrate minocycline. From a high resolution dataset at 2.3
Å, a structure was determined via molecular replacement using wildtype AcrB (Eicher,
PhD thesis) as template. In the dierence electron densities (Fo-Fc), at any sigma level,
there was no indication of crosslinks in any of the monomers. The distances of the Sγ
in the variant were 4.8, 4.8 and 5.3 Å, thus favourable for disulde bridge formation.
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Figure 3.5: Left: Localization of the engineered disulde bridge in the variant
AcrB_cl_S233C_Q726C based on the high resolution structure of the AcrB wt (pdb ID:
2GIF). The cysteine residues are on the Loop and the DC subdomain (green circle: Loop
of the L monomer (blue) and DC domain of the T monomer (yellow)). Right: N -
phenylnaphthylamine (NPN) eux by E. coli BW25113∆acrB synthesizing AcrB_cl (positive
control) or AcrB_cl_S233C_Q726C (Loop-DC). The NPN eux activity of the Loop-DC sub-
domain crosslinked variant was only slightly aected and addition of DTT was without eect.
MIC determinations conrmed these results [77].
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Inspection of the cysteine chains revealed a parallel rather than an approaching orien-
tation. Located on β-sheets, both residues may be aected by geometrical constraints
of these secondary structures and therefore show a minimal tendency to crosslink. This
nding is consistent with the low crosslinking eciency as shown by MALDI-TOF MS
[77]. Furthermore, there may be preferential crystallization of the crosslink free AcrB/-
DARPin protein pool within the sample. Superimposition of the S233C_Q726C variant
structure to the wildtype (pdb ID: 2GIF) showed no signicant deviation (RMSD =
0.812 Å, Table 3.2).
AcrB_cl_V225C_A777C, crosslink between Loop and DC subdomain
In AcrB_cl_V225C_A777C, disulde bridges were expected to form between the Loop
and the DC domain. The relative geometry of the cysteine side chains allows crosslinking
in all three conformations. In MALDI-TOF experiments crosslink rate was determined
more than 80% and it has been shown in MIC as well as in NPN eux experiments,
that this variant is fully functional [77]. This variant was successfully crystallized as
AcrB/DARPin complex and formed cubic crystals. A dataset to a resolution of 7.0
Å could be recorded and revealed the I23 (cubic) space group. Unit cell contains one
AcrB monomer with a bound DARPin molecule and coordinates could be determined
to be a=b=c=233.75 Å (Table 3.5). Phases were solved by molecular replacement using
a high resolution structure of a binding pocket variant of AcrB that as well could be
crystallized in the I23 space group (Eicher, PhD thesis). Interestingly, this space group
could only be observed in two individual AcrB binding pocket variants so far (Eicher et
al. , unpublished, Cha et al. , unpublished; see Chapter 5).
3.4 Discussion
During the process of purication of the various crosslink variants, a particular tendency
to form protein aggregations could be observed in the size-exclusion chromatography
proles of the AcrB variants containing inter- and intramolecular disulde bridges (not
shown). On the one hand, crosslink variants may be considered to be prone to aggre-
gate due to intermolecular disulde bridge formation, on the other hand introduction
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of crosslinking cysteines may induce alternative conformations that adversely aect sol-
ubility and lead to aggregation of the protein variants.
The AcrB_cl_Q229C_E585C variant (Loop-PC1 subdomain cross-link) (Figure 3.1)
was found to show unexpected high crosslinking rate in quantitative MALDI-TOF anal-
ysis (40%, Table 3.1) despite of suboptimal side chain orientations and distance of the
two cysteines judging from the in silico mutagenesis on basis of the high resolution
structure of the wildtype AcrB. Therefore, crystallization and high resolution structure
determination of this variant was pursued to understand the structural cause for this
unexpected crosslinking rate. However, eorts to produce well-diracting crystals did
not succeed so far. Loss of puried protein by precipitation and aggregation during
purication and preparation of crystallization indicate heterogeneity of this variant in
detergent solubilized form. The lack of a high resolution structure, visualizing the disul-
de bridge and the actual structural properties of the AcrB_cl_Q229C_E585C variant,
leaves us with speculation about the structural bases of the high crosslink rate. One
possibility for this nding is the structure of the (intermonomeric) loop, which may be
exible enough to allow deviances from the structure observed in the high resolution
map of the wildtype. This may reduce the distance between the two cysteine residues,
and a twist of the loop may also promote a favorable direction of the cysteine side
chain. The loop structure may be responsible for the trimerization of AcrB (section 2),
but direct involvement in the substrate transport process has not been anticipated thus
far. Compared to the wildtype, MIC data of the AcrB_cl_Q229C_E585C indicate
restriction in substrate eux, indicating a minor loss of functionality (Table 3.3). One
possibility might be the reduced synthesis of this variants in the E. coli cell leading to
reduced resistance. Moreover, the crosslink might lead to a restriction of the exibility
in the PC1 subdomain, resulting in the observed phenotype.
The crosslink variant AcrB_cl_V225C_A777C was designed to form disulde bridges
between the Loop structure and the DC domain in all three conformations [77]. The
crosslink rate was determined about 80% by MALDI-TOF MS. This crosslink, ap-
parently did not signicantly reduce AcrB activity as shown in MIC and NPN eux
experiments [77]. This variant supported the notion that the Loop-DC subdomain re-
gion was devoid of substantial rigid body movement (as opposed to the subdomains of
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the porter domain). However, the crystal structure of this Loop-DC crosslink variant
revealed some remarkable properties that have not been seen with fully functional AcrB
hitherto. Crystals grew in the space group I23, which has not been observed with the
wildtype AcrB crystals [7375]. Interestingly, two binding pocket variants of AcrB that
were crystallized in complex with DARPin binders in our group (Eicher et al. , unpub-
lished; Cha et al. , unpublished) showed very similar structural characteristics. The
high resolution structures of these binding pocket variants exhibited an all T state (in
which all three monomers within the AcrB trimer adopted the tight conformation). In
contrast to the previously described AcrB/DARPin complex [75], this binding pocket
variant bound three DARPins per AcrB trimer (see Chapter 2). Preliminary analysis of
the low resolution diraction data and subsequent molecular replacement indicated the
presence of one AcrB monomer with one bound DARPin within the asymmetric unit
(data not shown). These ndings suggest that this variant binds three DARPins per
AcrB trimer, just like the binding pocket variant. More detailed structural analysis of
this variant is not possible due to the poor resolution, but a putative 1:1 (AcrB:DARPin)
stoichiometry might indicate a similar "all-tight" conformation as observed in the bind-
ing pocket variants (Chapter 2).
In contrast to the structures of the S562C_T837C (PC2-TM7) variant, disulde bridges
could not be observed in the AcrB_cl_S132C_A294C (Figure 3.4) and AcrB_cl_
S233C_Q726C (Figure 3.5) variants. In quantitative MALDI-TOF experiments a cross-
linking rate of 41% was measured for AcrB_cl_S132C_A294C and in vivo MIC and
NPN eux experiments clearly showed the impact of the formed crosslink on drug eux
[77]. In the obtained structure of this variant, the distance between the Sγ atoms of
the cysteine residues in the L monomer was 7.64 Å, a distance expected to be too large
for disulde formation. Furthermore, the cysteine side chains are oriented away from
each other, a condition which would be disadvantageous for disulde bridge formation.
A certain exibility of the backbone in these regions can be assumed (e. g. during
conformational change from one state to the other) to allow the little distortion that
may allow the cysteines to reorientate for disulde formation. A possible explanation
for the absence of disulde bridges in the crystal structure may be that only the non-
crosslinked fraction of AcrB formed protein crystals.
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AcrB_cl_S233C_Q726C (Loop-DC subdomain cross-link variant) (Figure 3.5) was de-
signed as a functional control. In this variant, crosslinks between the loop and the DC
subdomain would form and persist in all three monomers telling from the distances
between the cysteine residues. In contrast to the expected high crosslink rate, the ac-
tual crosslinking was rather moderate. MALDI-TOF quantication revealed disulde
bridges in 17% of the monomers [77]. Additionally, this variant had slightly aected
NPN eux activity in vivo, compared to AcrB_cl, the positive control in these ex-
periments. However, the addition of DTT, a reducing agent, had no signicant ef-
fect on the activity of this variant (Figure 3.5, right). These data may indicate that
the somewhat reduced eux activity of the crosslink variant is not due to the estab-
lished disulde bridges, but rather due to the cysteine substitutions. However, the
results obtained from MIC experiments with other substrates of AcrB, indicated that
this variant exhibits wildtype (i. e. AcrB_cl) activity. In the high resolution data
from crystals AcrB_cl_S233C_Q726C, disulde bridges cannot be seen in any of the
monomers. One explanation might be that the lack of visible disulde bridges is due
to the low cross-linking rate. Alternatively, cross-link variants may selectively be ex-
cluded from the crystal growth process. The crystal structure obtained from the variant
AcrB_cl_S562C_T837C (PC2-TM7 cross-link variant) (Figure 3.3) was the most re-
vealing in this study. The introduced cysteines are located at the surface of the PC2
subdomain and the periplasmic end of the transmembrane helix TM7. In the O confor-
mation, the substituted residues approach each other to 3.3 Å distance [77]. Interest-
ingly, in the crystal structure, electron densities for both reduced cysteines as well as
disulde bridge forming cysteines can be observed (Figure 3.2). In the O conformation,
this partial crosslink seems not to have an inuence on the global conformation of the
monomer. Like the T monomer, the O monomer in this structure is identical to the
one in the asymmetric wildtype AcrB structure. In contrast, the monomer that adopts
the L conformation, shows considerable structural deviations caused by the crosslink.
Alignment of this conformation with the L conformation of the wildtype structure (pdb
ID: 2GIF) suggests that it constitutes an intermediate (I) conformation between the O
and the L conformation (Figure 3.3). Despite the new conformation, observed in the
PC2 subdomain of the L conformer of AcrB_cl_S562C_T837C, DARPin binding was
not aected.
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The PC2 subdomain is comprised of two α-helices (Cα3 and Cα8) and two pairs of
antiparallel β-sheets (Cβ6 and Cβ14, Cβ5 and Cβ15) (Figure 3.3, right). In the con-
text of the conformational changes during the transport cycle, subdomains of AcrB are
considered as rigid body entities that undergo spatial rearrangements. The crosslink in
the L monomer of AcrB_cl_S562C_T837C seems to arrest the PC2 subdomain before
it can adopt the position observed in the L monomer of the wildtype. The change from
the O to the L conformation features a tilting of the PN1 and PC2 subdomains towards
the PN1-PN2 interface of the O monomer. In the new conformation of the crosslink
variant, the PN1 subdomain already adopted the O monomer position, whereas the
PC2 subdomain is constrained by the disulde bridge and got halted during the re-
orientation. This nding gives rise to new insights into the rearrangement of the PN1
and PC2 porter subdomains during the conformational cycling. It is conceivable, that
these two subdomains are largely independent of each other in their conformational
rearrangement. Furthermore, it seems reasonable to think of a serially concerted move-
ment. PN1 may initially move to adopt its new location, to make subsequently way
for the reorientation of the PC2 subdomain. The tilting of the PN1 subdomain is one
of the prominent subdomain features during the conversion from T to O and from O
to L. The PN1 subdomain tilting was suggested to be a measure to occlude the exit
path of the neighboring T conformer where substrate has bound in the binding pocket
[73]. The concomitant movement of the PC2 subdomain, as implied for wildtype AcrB
conformational cycling, results in the closure of the lateral cleft and appears to pre-
vent extrusion of the substrate laterally via the tunnel towards the periplasm. In the
PC2-TM7 crosslink variant, the latter conformational change is prohibited and might
stall the eective eux of substrates towards TolC. Whether the movement of PN1 and
PC2 is sequential i. e. whether the movement of the PN1 precedes that of the PC2
subdomain appears likely, but cannot be postulated with absolute certainty. Moreover,
this intermediate conformation still cannot give exclusive information on the direction
of cycling, e. g. from L to T to O and back to L.
In summary, the presented data shows substantial new information based on the struc-
tures of one AcrB crosslink variant, demonstrating an intermediate conformation of the
porter subdomain PC2 possibly representing a cycling intermediate state and another
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structure which might represent a fully functional cross-linked AcrB in a symmetric
intermediate state.
3.5 Material and Methods
Bacterial strains and plasmids and growth conditions
Cloning procedures were done in the E. coli strain DH5α [133] using LB medium [134]
supplemented with corresponding selective antibiotics. The pET24 plasmid was used
as backbone in cloning, mutagenesis and expression of AcrB. All AcrB variants were
expressed in E. coli C43 (DE3) [135] using phosphate buered TB medium. The E. coli
strain BW25113∆acrB [77] was used for the NPN eux assay and drug susceptibility
tests.
Site-directed mutagenesis
All constructs are based on a cysteine free variant of AcrB (C493A_C887A, AcrB_cl)
[77]. Cloning procedures were performed on the pET24_AcrB_cl
His
plasmid, a variant
of the pET24_AcrB
His
[125] carrying the AcrB_cl. The cysteine pairs were consec-
utively introduced by site-directed mutagenesis using the Quikchange protocol from
Stratagene. All constructs were veried by sequencing at Microsynth Laboratory (Bal-
gach, Switzerland).
N-Phenylnaphthylamine (NPN) eux assay
The NPN eux experiments were performed as previously described [77]. Cultures
of E. coli BW25113∆acrB harbouring pET24 carrying the AcrB variants were grown
in LB medium supplemented with 50 µg·ml-1 kanamycin at 37 °C and 280 rev·min-1
to an OD
600
of 0.80.9, cells were harvested and resuspended in 4 ml buer (50 mM
KP
i
pH 7, 1 mM MgSO
4
) and de-engergized by addition of 200 µM carbonyl cyanide
m-chlorophenylhydrazone (CCCP) for 10 min on ice. Cells were washed three times
with 4 ml buer to remove CCCP. Fluorescence traces were recorded on a Varian Cary
Eclipse uorescence photospectrometer at RT. Excitation and emission wavelengths
80
3 Manuscript: Crystal Structures of AcrB Crosslink Variants
were 355 and 420 nm, respectively and sensitivity was set to 700 V. Measurements were
conducted in 2 ml buer, cell densities were adjusted to an OD
600
of 0.2 and NPN
(10 µM) (and DTT (10 mM), where required) were added. After NPN uorescence was
followed to saturation, glucose (0.2% w/v) was added and traces were recorded.
Drug susceptibility test
Determination of minimal inhibitory concentration (MIC) was carried out as previously
described [77]. Basically, E. coli BW25113∆acrB harbouring pET24 carrying the AcrB
variants were pre-grown to an OD
600
of 0.60.8 in LB medium supplemented with
kanamycin (50 µg·ml-1). These cultures were used to inoculate (1:100) 96-well microtiter
plates containing 150 µl LB with kanamycin and the indicated drug. Cells were grown
for 22 hours at 37 °C and 160 rev·min-1. OD
600
was measured before and after growth
period and the lowest antibiotic concentration where cultures displayed an OD
600
less
than 0.2 was dened as the minimal inhibitory concentration.
Purication and crystallization of AcrB crosslink variants
Overexpression and membrane preparation of AcrB was carried out as previously de-
scribed [74] with modications. DARPins (inhibitor 1108_19 [75]) were puried ac-
cording to [136]. During solubilization and purication n-dodecyl-β-maltoside (DDM,
GLYCON Biochemicals GmbH, Luckenwalde, Germany) was exclusively used as deter-
gent. Membranes were solubilized in 20 mM Tris, 150 mM NaCl, 10 mM imidazole,
10% glycerol and 2% DDM, pH 7.5. The soluble fraction was applied to a Ni
2+
-NTA
anity column (Ni-NTA Agarose Quiagen, 2 ml bed volume) pre-equilibrated in buer1
(20 mM Tris, 150 mM NaCl, 10 mM imidazole, 10% glycerol, pH 7.5). The column was
washed with 45×column volume (CV) buer1 and subsequently washed with 30xCV
buer2 (20 mM Tris, 150 mM NaCl, 50 mM imidazole, 10% glycerol, pH 7.5). AcrB
was eluted in buer3 (20 mM Tris, 150 mM NaCl, 200 mM imidazole, 10% glycerol,
pH 7.5). DARPins were added to the puried AcrB in a two-fold molar excess. Concen-
trated samples were subjected to size-exclusion chromatography (20 mM Tris, 150 mM
NaCl, 0.03% DDM, pH 7.5) using a GE Superdex 200 10/300GL column coupled to a
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GE Healthcare ÄKTAprime system (at 0.5 ml·min-1 ow rate). Peak fractions corre-
sponding to the AcrB/DARPin complex were collected and concentrated. Concentration
steps were performed in centrifugal lter devices with a cuto size of 100 kDa (Ami-
con Ultra, Millipore). During concentration, buer exchange to HEPES buer (10 mM
Na-HEPES, 50 mM NaCl, 0.03% DDM, pH 7.5) was performed.
Table 3.4: Crystallization conditions and co-crystallized substrates of AcrB crosslink crystals
obtained in this study. All crystals grew in co-crystallization setups with specic DARPin
binders.
crystal cryst. condition substrate
AcrB_cl_Q229C_E585C various conditions (100 mM Na-
HEPES pH 7.5, 200 mM CaCl
2
,
3656% PEG400)
-
AcrB_cl_S562C_T837C 0.05 M ADA
a
pH 6.4, 0.2 M
NH
4
SO
4
, 9% PEG4000, 4%
glycerol
-
AcrB_cl_S132C_A294C 0.05 M ADA pH 6.5, 0.2 M
NH
4
SO
4
, 8% PEG4000
-
AcrB_cl_S233C_Q726C 0.05 M ADA pH 6.5, 0.2 M
NH
4
SO
4
, 7% PEG4000, 3.4%
glycerol
2 mM minocycline
(from 50.61 mM stock
in water)
AcrB_cl_V225C_A777C 25% PEG400, 0.05M Na-acetate
pH 4.5, 15% glycerol
-
a
: N -(2-Acetamido)iminodiacetic acid
Crystals were grown in hanging drop vapor diusion setups at 17 °C. Crystallization
conditions and substrate supplementation are listed in Table 3.4. Protein sample and
crystallization conditions were mixed in equal amounts for the hanging drop. Before
freezing in liquid nitrogen, crystals were cryoprotected by stepwise soaking the crystals
for 3 minutes with increasing (5% steps) glycerol concentrations up to 30%. Cryopro-
tection was omitted when crystallization solutions were considered to provide sucient
cryoprotection (e. g. ≥ 25% PEG400).
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X-ray diraction dataset analysis and renement procedure
Dataset were collected at the beamline X06SA of the Swiss Light Source (SLS) at the
Paul Scherrer Institut, Villigen, Switzerland at a wavelength of 1 Å. Data reduction
was done with the XDS package [137]. The structures were determined by molecu-
lar replacement using MOLREP [138]. Renement was done with PHENIX [139] and
REFMAC 5 [140] using rigid body renement and restrained renement with TLS re-
straints. Models were built in COOT [141]. Figures were composed using PyMOL 1.2
(The PyMOL Molecular Graphics System, Schrödinger, LLC.).
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Table 3.5: Crystallographic and renement data of AcrB crosslink variants.
AcrB_cl_
S562C_T837C S132C_A294C S233C_Q726C V225C_A777C
Ligands DARPin DARPin DARPin, minocyclin DARPin
Data collection
Space group P2
1
2
1
2
1
P2
1
2
1
2
1
P2
1
2
1
2
1
I23
Cell dimensions
a (Å) 145.78 148.27 146.06 233.75
b (Å) 163.51 162.98 163.42 233.75
c (Å) 245.11 248.05 246.35 233.75
α=β=γ (°) 90 90 90 90
Resolution (Å) 2.5 (2.632.48) 2.5 (2.642.49) 2.3 (2.432.30) 6.9 (7.296.89)
R
meas
(%) 11.6 (137.9) 18.9 (70.2) 15.3 (65.5) 7.1 (181.7)
I/σ
I
9.54 (1.70) 8.97 (2.33) 10.24 (2.06) 25.1 (1.80)
Completeness (%) 99.3 (96.0) 99.3 (96.5) 92.8 (77.4) 98.0 (89.6)
Redundancy 7.3 (6.3) 6.7 (6.6) 4.9 (4.1) 19.5 (18.0)
Renement AcrB wt AcrB wt AcrB wt AcrB_V612F
trimer model Eicher PhD Thesis
Program PHENIX PHENIX PHENIX PHENIX
& REFMAC & REFMAC & REFMAC & REFMAC
Resolution (Å) 49.02.5 30.12.5 29.82.3 29.97.0
No. of reections 201942 206415 242662 3017
R
work
19.61 20.28 21.73 26.51
R
free
24.47 25.71 26.43 46.81
N. atoms
macromolecule
residues 27537 27147 27604 9115
solvent
residues 1300 640 1034 -
B-factors
macromolecule 47.24 57.60 56.47 -
solvent 41.80 47.72 45.17 -
overall 46.97 57.33 56.06 81.94
RMS deviations
bond length (Å) 0.008 0.008 0.008 0.015
bond angles (°) 1.145 1.215 1.166 1.943
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4.1 TolC: β-barrel deletion variant
The AcrAB-TolC drug eux system from E. coli is mutally dependent on the presence
of all its components [142]. Chromosomal deletion of one of the genes coding for any
of the three components causes a complete loss of drug resistance in E. coli. Since the
active tripartite system exports drugs from the periplasm over the outer membrane,
lack of any of the three components will exhibit the same phenotype yet for dier-
ent reasons. E. g. deletion or fatal mutation of the acrA gene might hamper pump
assembly, yet the AcrB component might still be able to pump drugs. In this case,
the drugs (e. g. β-lactams) might be pumped in a futile cycle from the outer leaet
of the inner membrane to the periplasm, having no net eect on the concentration of
the drugs inside the periplasm. Alternatively, one can assume that only the assembled
tripartite AcrAB-TolC complex is mechanistically capable to work as an active trans-
porter. To test the latter hypothesis, the aim was to reconstitute an in vitro tripartite
setup without the imperative for having two membranes, as present in the natural sit-
uation in the Gram-negative cell. Therefore, the transmembrane β-barrel domain of
TolC was deleted to produce a soluble TolC channel, still capable to bind to AcrB,
which would resemble the native complex without the need of a second membrane. The
β-barrel is formed by three TolC monomers, each contributing two loops that consist of
two β-strands and a connecting turn. Such a soluble, β-barrel-less TolC variant lacking
the membrane-embedded domain was generated. Residues constituting the two β-barrel
loops, designated loop1 and loop2, were identied using the 3-D structural pdb le 1EK9
(www.pdb.org) from Koronakis et al. [98]. Proline residues were chosen beginning and
end of the β-strands. A TolC trimer is shown in Figure 4.1 in cartoon representation.
One monomer is highlighted in green color. The deleted range of residues on the cor-
responding loop1 and loop2 are shown in cyan and magenta, respectively. To remove
the β-barrel membrane domain, the loops were deleted by site-directed mutagenesis
and concomitantly replaced by polyglycine linkers to connect the periplasmic domains
in the variant soluble protein. Plasmid pBRtolC (pBR322 with tolC gene, courtesy
of J. Fralick) was used as template to perform site-directed mutagenesis according to
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Figure 4.1: Visualization of the TolC trimer in cartoon representation. One monomer is
highlighted in dierent colors. The β-barrel embedded in the outer membrane is composed of
two loops (consisting of two antiparallel β-sheets) from each of the three monomers. Deleted
residues of loop1 and loop2 are shown in cyan and magenta, respectively (pdb ID: 1EK9). The
gray bars indicate the outer membrane of E. coli (about 25 Å thick).
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the Quikchange protocol (Stratagene) in two consecutive steps. The primers used for
these deletions are shown in Table 4.1. The codons encoding for inserted glycine link-
Table 4.1: Primers used for site-directed mutagenesis for the creation of the deleted loop TolC
variant. Glycine (codon: GGC) linkers that replace the loops are underlined (loop1: 4x Gly;
loop2: 2x Gly).
Name Sequence
tolC_dl1_for 5'-AAG CGC GCA GTC CAT TAC TGC CAG GCG GCG GCG GCT
TTG ATA TGT CGA AAT GGC GT-3'
tolC_dl1_rev 5'-ACG CCA TTT CGA CAT ATC AAA GCC GCC GCC GCC TGG
CAG TAA TGG ACT GCG CGC TT-3'
tolC_dl2_for 5'-CAG GAT GGT CAC TTA CCG ACT GGC GGC CCG ATT TAT
CAG GGC GGA ATG GTT-3'
tolC_dl2_rev 5'-AAC CAT TCC GCC CTG ATA AAT CGG GCC GCC AGT CGG
TAA GTG ACC ATC CTG-3'
ers, four in place of loop1 and two in place of loop2, are underlined. The length of
the linkers were chosen based on the distance between the loop-anking residues in the
crystal structure [143]. Site-directed mutagenesis products were veried by sequencing.
The gene coding for TolC β-barrel less variant, designated tolC_bl was cloned into
the pET24 vector (Novagen) for expression studies. Expression from the pET24 vector
resulted in a β-barrel less TolC including a histidine-tag at the C-terminal end of the
construct. In E. coli BL21 (DE3), expression could be detected by subjecting whole
cell lysates to SDS-PAGE analysis (Figure 4.2, left panel). The construct resulted in
the synthesis of a protein of about 50 kDa (calculated protein mass: 46.05 kDa). To
investigate the localization of the construct within the cell, periplasmic protein extrac-
tion was performed [144]. The protein could be detected in whole cell lysates (Figure
4.2, left panel); the periplasmic fraction contained only trace amounts (not shown),
indicating poor export of the variant to the periplasm despite the signal sequence at
the N-terminus. In a next step, E. coli BL21(DE3) cells overproducing TolC_bl from
pET24 were disrupted in the Emulsiex cell disruptor and the low-spin supernatant was
loaded on a Ni
2+
-NTA purication column. Small amounts of puried protein could be
eluted from the column (Figure 4.2, left panel) which was prone to precipitation upon
concentration. Size-exclusion chromatography revealed that the retention time of the
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protein peak of puried TolC_bl corresponded to about 4050 kDa, indicating that the
puried construct was existent as a monomer (Figure 4.2, right panel).
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Figure 4.2: Left panel: SDS-PAGE gel like representation (Agilent protein 230 chip, Agilent
Bioanalyzer 2100). Lanes: 1 protein ladder, 2 whole cell lysate, 3 pellet and 4 supernatant from
low spin centrifugation after cell disruption, 5 eluate from Ni
2+
-NTA column. TolC_bl (*)
displays an electrophoretic mobility of about 50 kDa. Bands at 240 and 4.5 to 7 kDa (arrows)
correspond to system signals and do not represent protein. Right panel, top: Size-exclusion
prole of puried TolC_bl. Peak at 16 ml elution volume corresponds to monomeric TolC_bl.
Peaks at 21 ml and later may represent degradation product or buer additives. Right panel,
bottom: Superimposition of size-exclusion proles of puried TolC_bl (blue) and a calibration
solution (red). The main peak of the puried TolC_bl corresponds with the 43 kDa peak of the
calibration. Size exclusion chromatography was performed using a GE Superdex 200 10/300GL
column coupled to a GE Äkta Prime FPLC at a ow rate of 0.5 ml·min-1.
In 2008, Kim et al. used a similar approach to also synthetize the periplasmic domain
(β-barrel less) of TdeA of Actinobacillus actinomycetemcomitans, a member of the TolC
family [145]. The construct from Kim et al. contained a three residue smaller loop1 and
a 6 residue smaller loop2 compared to our TolC construct. Moreover, the introduced
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linkers dier as well and are SGSGS and SGSGSG replacing loop1 and loop2, respec-
tively. In Figure 4.3 an alignment of the loop regions of wildtype TolC, TolC_bl of this
study and the TdeA variant (TdeA_bl) from Kim's study is shown. Identical residues
loop1 loop2
60
.
70
.
80
.
90
.
100
.
TolC LLPQLGLGADYTYSNGYRDANGINSNATSASLQLTQSIFDMSKW GHLPT
TolC_bl LLPGGGG...............................FDMSKW GHLPT
TdeA LVPSGSGS.................................AEW SWFSG
loop2
270
.
280
.
290
.
300
.
310
.
TolC LDLTASTGISDTSYSGSKTRGAAGTQYDDSNMGQNKVGLSFSLPIYQGGM
TolC_bl GG.........................................PIYQGGM
TdeA SGSG............................................NT
320
.
TolC V
TolC_bl V
TdeA V
Figure 4.3: Alignment of the loop regions of TolC of E. coli, TolC_bl from this work and
TdeA_bl from Kim et al. [145]. The range of the two β-barrel loops are indicated. Identical
residues are shown blue; the red bar represents the gap of intervening sequence (AA 104
264). The introduced linker sequences are shaded green. Alignment was performed with the
ClustalW2 program (www.ebi.ac.uk/Tools/clustalw2/index.html).
are shaded blue. Loop regions designated in Kim's study are indicated and introduced
linker sequences are shaded green. Kim et al. [145] succeeded in the synthesis and pu-
rication of the soluble β-barrel less TdeA variant. Electron microscopy showed that
the α-helical part of the protein was correctly folded despite the lack of the membrane
domain.
4.2 Reconstitution experiments and experiments with inverted vesicles
from E. coli
Despite detailed structural insights, functional data on binding anities of substrates
and kinetic parameters on drug transport by AcrB are sparse. The main bottleneck here
is the lack of suitable in vitro binding and transport assays. There are several approaches
to study the transport activity of transporters in membranes and membrane-like struc-
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tures: e. g. experiments using vesicles, proteoliposomes containing reconstituted experi-
ments and electrophysiology. Initial experiments to investigate drug transport by AcrB
in vitro, using inverted bacterial vesicles and liposomes containing reconstituted AcrB,
have been done and are presented in the following sections.
Experiments with inverted vesicles from E. coli
Inverted vesicles (IV) were generated from E. coli cells using the French pressure cell
at 18,000 psi. During preparation, the orientation of the membrane components is
inverted compared to the situation in vivo. This method was shown to result in an
inside-out situation in 95% of the generated vesicles [146]. These IVs still contained all
constituents of the native bacterial membrane but outward facing proteins were turned
against the inside lumen of the vesicles. IVs generated from cells containing AcrB were
used to study transport of AcrB substrates. Energy was provided by ATP, which was
consequently used by the intrinsic F
1
F
O
-ATPase to generate a proton motive force that,
theoretically, is able to drive transport of drugs by AcrB (Figure 4.4, left panel).
Inverted vesicles were generated from E. coli BW25113∆acrB (DE3) overexpressing
AcrB from the plasmid pET24_AcrB. The ability of vesicles to generate a transmem-
brane proton gradient from primary source (ATP) and tightness to keep up the gradi-
ent was tested with the uorescent dye 9-amino-2-chloro-6-methoxy acridine (ACMA).
ACMA uorescence quenching is a method to sense ∆pH over bacterial membranes
[147]. ACMA uorescence in vesicles was quenched when a proton gradient is formed
over the membrane (inside acidic) and is re-established as soon as the proton gradient
dissipates. Upon ATP addition to suspended vesicles, quenching of ACMA could be
observed (Figure 4.4, right panel). This quenching indicated the activity of bacterial
F
1
F
O
-ATPase and conrms the membrane integrity able to sustain a ∆pH gradient.
When carbonylcyanide-m-chlorophenylhydrazon (CCCP) was added to the vesicles, a
decrease in the quenching, hence increase of uorescent signal could be observed. CCCP,
an uncoupling agent, dissipates the electrochemical proton gradient in membrane vesi-
cles. Further addition of ammonium chloride totally collapsed the remaining ∆pH by
acidifying the outside of the vesicles (and consuming internal protons). The uorescence
signal was almost restored to the level before ATP addition.
90
4 Supplementary Experiments
0
50
100
150
200
250
300
350
0 200 400 600 800 1000 1200
fl
u
o
re
s
c
e
n
c
e
time [sec]
Figure 4.4: Left panel: Working hypothesis with inverted vesicles. In inverted vesicles mem-
brane proteins are reversely oriented compared to the physiological situation. Addition of ATP
to the outside activates the bacterial F
1
F
O
-ATPase generating an electrochemical proton gradi-
ent (∆pH and ∆Ψ) over the membrane vesicles, resulting in the accumulation of protons at the
inside of the vesicles. AcrB in turn would theoretically be able to consume these protons while
transporting substrates, according to the current hypothesis, from the inner leaet of the inside
vesicles to the vesicle lumen. Alternatively and currently not experimentally excluded, substrate
might be transported from the outside to the interior of the inside-out vesicles. Right panel:
ACMA uorescence signal in inverted membrane vesicles obtained from E. coli BW25113∆acrB
(DE3) overexpressing AcrB. ACMA is a uorescent dye that distributes into the dierent com-
partments of the assay system (outside, membrane and inside) and its uorescent signal is
quenched as a result of proton accumulation inside the vesicles due to the action of the F
1
F
O
ATPase in the presence of ATP. Both carbonylcyanide-m-chlorophenylhydrazon (CCCP) and
ammonium chloride dissipate the established proton gradient resulting in a restored uorescent
signal.
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The electrochemical proton gradient generated by the F
1
F
O
-ATPase theoretically pro-
vides energy for AcrB transport activity. Experiments were performed to trace the
transport of AcrB substrates either via uorescent substrates directly, or indirectly, via
consumption of the proton gradient. Direct measurements made use of the uorescent
properties of the AcrB substrate N -phenylnaphthylamine (NPN). NPN, added to mem-
branes in aqueous solution readily inserts into these membranes and exhibits strong
uorescence. In cells, AcrB removes NPN from the membrane and expels it to the out-
side of the cell, where NPN's uorescence is strongly decreased due to the lack of the
hydrophobic environment. Consequently, the transport of NPN can be traced via u-
orescence measurements [77]. However, in these experiments AcrB substrate transport
could neither be detected directly (by NPN uorescence) nor indirectly (by measuring
proton consumption via ACMA uorescence).
Reconstitution experiments
In E. coli, beside AcrB, there are other multidrug eux pumps that have an overlapping
substrate specicity. The reconstitution of AcrB into liposomes provides some consid-
erable advantage over inverted vesicles experiments: a controlled liposome system with
AcrB as the only protein present.
Puried wt AcrB and a non-functional AcrB variant (AcrB_D407N/D408N (AcrB nf),
negative control) were reconstituted into Triton X-100 destabilized liposomes. As ad-
ditional negative control, destabilized liposomes were supplemented with AcrB sample
buer. The integration of AcrB was checked with a 2100 Bioanalyzer (Agilent Technolo-
gies Inc.) using the Agilent Protein 230 chip (Figure 4.5). Data from the protein chip
indicated that AcrB is associated with the liposomes after the reconstitution process.
In the systemic negative control no signal of protein is observed. However, detailed
information about the orientation or whether insertion resembles the situation in the
bacterial membrane, cannot be drawn from these experiments.
The integrity of the membranes of the proteoliposomes was tested using the uorescent
dye 3,3'-diethyloxacarbocyanine iodide (DiOC
2
(3)) [148]. The uorescence signal of this
dye shifts in the presence of a membrane potential. Proteoliposomes, loaded with potas-
92
4 Supplementary Experiments
Figure 4.5: SDS-PAGE gel like representation (Agilent protein 230 chip, Agilent Bioanalyzer
2100) of liposomes with reconstituted protein. Lanes: 1. protein size ladder, 2. liposomes with
AcrB wt, 3. liposomes with non-functional (nf) AcrB and 4. empty liposomes (reconstitution
process with AcrB sample buer). (*) indicates the electrophoretic mobility of the AcrB protein
band at about 90 kDa. The signals between 7 and 15 kDa derive from the lipids and are not
observed in liposome free samples (not shown). Signals between 4.5 and 7 kDa and at 240 kDa
correspond to system signals and do not represent protein.
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sium phosphate buer, were resuspended in N -Methyl-D-glucamine (NMDG)-HEPES
buer and a potassium diusion membrane potential was generated by addition of vali-
nomycin (1 µM). The uorescence emission of DiOC
2
(3) increased as the membrane
potential established and a stable plateau was achieved. The addition of KCl dimin-
ished the potassium diusion potential and the uorescence signal decreased to the
initial value (Figure 4.6). This data provides evidence that the membranes of the AcrB
proteoliposomes were capable of maintaining a stable membrane potential.
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Figure 4.6: Fluorescence trace of a DIOC
2
(3) experiment with proteoliposomes with reconsti-
tuted wildtype AcrB to test the capability of the liposome membranes to retain a membrane po-
tential (leak-tight proteoliposomes). Proteoliposomes loaded with potassium phosphate buer
were resuspended in N -Methyl-D-glucamine (NMDG)-HEPES buer. The uorescent agent
DIOC
2
(3) was added to the resuspended liposomes. The addition of valinomycin generated a
potassium diusion membrane potential that increased the uorescence of the membrane po-
tential sensitive DIOC
2
(3). Addition of KCl diminished the membrane potential and resulted
in a decrease of the uorescence to the initial value.
Transport experiments with the H
+
/substrate antiporter AcrB require a proton gradi-
ent over the membranes of liposomes with reconstituted protein. A ∆pH and a ∆pH/∆Ψ
combined were generated in the experimental setups. The uorescent substrates Hoechst
33342 and N -phenylnaphthylamine (NPN) were used to follow transport activity in the
reconstituted setup. Both dyes are lipophilic molecules that immediately associate with
phospholipid membranes. The ability of these substances to exhibit high uorescence in
hydrophobic environments and signicantly lower uorescence in aqueous environment
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makes them valuable for studying AcrB drug transport. The rationale is that the dyes
integrate into the membranes of the proteoliposomes, where they show strong uores-
cence. When these molecules are transported from the membrane to the lumen or the
outside of the liposomes, their uorescence signals are quenched. Despite considerable
eorts, transport of Hoechst 33342 and NPN by AcrB could not be observed.
Hoechst 33342 has been used in many occasions to measure secondary multidrug trans-
port e. g. [149]. Yu et al. employed the dye for transport experiments in inverted vesicles
and liposomes enriched with NorA, a H
+
/substrate antiporter of the major facilitator
superfamily (MFS). In their work, they were able to demonstrate quenching of Hoechst
33342 uorescence in proteoliposomes by NorA transport upon the generation of a pro-
ton gradient.
The inability to trace Hoechst 33342 or NPN uorescence quenching by AcrB trans-
port may be due to several reasons. On the one hand, the activity of AcrB may be
non-existent or too slow in a reconstitute system described above. In vivo, it has been
reported that the AcrA/AcrB/TolC complex is inactive if any of the three proteins is
non-functional [142]. In a reconstitute system, isolated AcrB may therefore be inactive
too. On the other hand, Hoechst 33342 transport observed in NorA containing pro-
teoliposomes [149] may signicantly dier from that in AcrB proteoliposomes. NorA
probably transports substrates from the lumen (or inner membrane leaet) across the
membrane to the outside of the liposomes, whereas AcrB hypothetically features trans-
port from the outer leaet to the outside. Redistribution of the expelled dye from
the outside into the outer leaet is a quick process and may exceed AcrB's transport
capabilities resulting in a futile transport cycle, where no change in uorescence is de-
tectable. In a NorA reconstitute system, the dye would not only have to redistribute
into the outer leaet of the membrane but additionally relocate into the inner leaet
via slow ip-op processes.
4.3 Materials and Methods
Protein expression and purication TolC_bl was generated using site directed muta-
genesis based on the Quikchange protocol from Stratagene. Loop1 and 2 were removed
95
4 Supplementary Experiments
in two consecutive PCR reactions. The resulting product was veried by sequenc-
ing. Chemical competent E. coli BL21 (DE3) cells were transformed with the plasmid
pET24_tolC_bl. Overexpression was performed in Terric Broth medium and initi-
ated by the addition of 0.5 mM IPTG at OD
600
=1. After four hours at 18 °C, cells were
harvested and resuspended in 20 mM Tris/Cl, pH 8 containing 500 mM NaCl, 2 mM
MgCl
2
, 0.2 mM diisopropyluorophosphate and trace amount of DNaseI and passed
three times through the EmulsiFlex
®
-C5 (Avestin Inc.) at 10-15 kpsi. Cell debris
was separated by centrifugation at 9,000×g for 10 minutes. Supernatant was applied
to a Ni
2+
-NTA column (Ni-NTA Agarose Qiagen) pre-equilibrated in buer1 (20 mM
Tris/Cl, pH 7.5, 150 mM NaCl, 10 mM imidazole, pH 7.5, 10% glycerol). The column
was washed with 35 ml buer1 and subsequently washed with 30 ml buer2 (20 mM
Tris/Cl, pH 7.5, 150 mM NaCl, 50 mM imidazole, pH 7.5, 10% glycerol). TolC_bl
was eluted in 6 ml buer3 (20 mM Tris/Cl, pH 7.5, 150 mM NaCl, 200 mM imida-
zole, pH 7.5, 10% glycerol) and concentrated 8.5 fold. 4 µl of non-concentrated whole
cell lysates, centrifugation pellet, supernatant and elution fraction were loaded on an
Agilent protein 230 chip (Agilent Bioanalyzer 2100) for qualitative evaluation.
Size-exclusion chromatography Concentrated protein sample (0.9 mg·ml-1; 0.7 ml)
was subjected to size exclusion chromatography (running buer: 20 mM Tris/Cl, pH 7.5,
150 mM NaCl) using a GE Superdex 200 10/300GL column coupled to a GE Äkta Prime
FPLC. Size-exclusion chromatography was performed at a ow rate of 0.5 ml·min-1 and
fractions of 0.5 ml were collected.
ACMA uorescence measurements Bacterial membranes containing 200 µg total
protein were suspended in 10 mM KP
i
, pH 7.5, 10 mM MgSO
4
(2 ml) and constantly
stirred during measurements. Fluorescence traces were recorded in a RF-5301 PC spec-
trouorophotometer (Shimadzu) at excitation and emission wave lengths of 430 nm and
474 nm, respectively, using 5 nm slit width in both, excitation and emission. 9-amino-
2-chloro-6-methoxy acridine (ACMA, 0.25 µM), 1 mM ATP, 5 µM carbonylcyanide-m-
chlorophenylhydrazon (CCCP) and 10 mM NH
4
Cl (nal concentrations) were added
when indicated.
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Protein expression and purication AcrB was expressed and puried from E. coli
C43 (DE3) cells as described previously [74, 125]. After purication via Ni
2+
-NTA
anity chromatography, AcrB was reconstituted into liposomes.
Generation of inverted vesicles from E. coli pET24 vectors carrying the wildtype and
non-functional variant of AcrB were transformed into E. coli BW25113∆acrB (DE3)
and AcrB protein was overexpressed in these cells in LB medium with 0.5 mM IPTG.
After four hours at 27 °C, cells were harvested and resuspended in 20 mM Tris/Cl, pH 8
containing 500 mM NaCl, 2 mM MgCl
2
, 0.2 mM diisopropyluorophosphate and trace
amount of DNaseI and passed three times through the French pressure cell at 1200 psi
gage pressure which corresponds to 18,000 psi cell pressure when using a 1
”
piston. Cell
debris was separated by centrifugation at 9,000×g for 10 minutes. Inverted membrane
vesicles were collected at 150,000×g for 60 minutes at 4 °C, resuspended in 50 mM KP
i
,
pH 7.5 and stored at -80 °C.
Reconstitution of AcrB Preparation and reconstitution was carried out according to
the protocol of Geertsma et al. [150] with adaptations. Bio-Beads SM-2 Adsorbent (5 g,
Bio-Rad) were consecutively washed with 100 ml methanol, 100 ml ethanol and degassed
in 100 ml water (bidest). Then the bead slurry was washed 10 times in 100 ml water
(bidest). Prepared beads were stored at 4 °C submersed in water. Lipids that were used
in these experiments were L-α-Phosphatidylcholine from soy bean (P5638, Sigma), E.
coli total lipid extract (100500C, Avanti Polar Lipids, Inc.) and a E. coli total lipid
extract: L-α-phosphatidylcholine (Egg, Chicken, 840051C, Avanti Polar Lipids, Inc.)
of 3:1 (w/w). Stock solutions of lipids in chloroform were mixed in desired ratios.
Mixture was dried using a rotary evaporator, subsequently washed in diethyl ether
and dried again. Dried lipid mixture was resuspended in buer (for example 50 mM
KP
i
, pH 6.5) to a nal concentration of 20 mg·ml-1 at room temperature using 45 °
bent 20-gauge needle. Lipid suspension was sonicated 6 times (15 s + 45 s pause)
at a peak-to-peak intensity of 4 µm on ice. Samples were kept under a stream of
nitrogen gas during sonication. Generated small unilamellar vesicles (SUVs) were
ash-frozen and gently thawn 3 times at room temperature to obtain large multilamellar
vesicles (LMVs). LMVs were ash-frozen in 0.5 ml aliquots and stored in liquid nitrogen.
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For reconstitution, LMVs (20 mg·ml-1) are thawn and extruded through a 400 nm
lter 11 times to generate large unilamellar vesicles (LUVs) which were subsequently
diluted to 4 mg·ml-1 with the buer used for resuspension of the lipids. LUVs were
titrated to R
sat
with 10 µl aliquots of 10% (wt/vol) Triton X-100. Another 5 aliquots
of Triton X-100 were added (R
work
) to destabilize the liposomes (Figure 4.7). For a
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Figure 4.7: Light scattering of large unilamellar vesicles at OD
540
at increasing Triton X-100
concentrations. R
sat
and working concentration (R
work
) for reconstitution were obtained at
about 3 and 4.5 mM Triton X-100, respectively.
1:100 (wt/wt) protein to lipid ratio, 0.2 ml of puried AcrB (1 mg·ml-1 in 50 mM
KP
i
, pH 7.8, 20% glycerol, 200 mM NaCl, 500 mM imidazole, pH 7.5, 0.03% DDM)
were added to 5 ml detergent destabilized liposomes and incubated on a blood wheel
gently agitating for 15 minutes at RT. Bio-Beads (200 mg wet weight) were added to
the protein-liposome suspension and the mixture was incubated 30 minutes at RT .
In additional two steps, 200 mg Bio-Beads were added each and incubated at 4 °C for
60 minutes and overnight, respectively. After overnight incubation, another 200 mg
Bio-Beads were added to the sample, followed by incubation for 120 minutes at 4 °C.
Incubation steps were performed on a bloodwheel, gently agitating. The suspension
was ltered from the beads using a gravity ow column equipped with one frit (sintered
glass). Beads were washed with 45 ml 50 mM KP
i
, 2 mM MgSO
4
, pH 6.5, and the
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owthrough was used to dilute the proteoliposome suspension to lower the glycerol
concentration. Proteoliposomes were collected by centrifugation in a TFT65.38 Sorvall
rotor at 50,000 rpm (175,000-200,000×g) and 4 °C for 60 minutes and subsequently
resuspended in 1 ml 50 mM KP
i
, 2 mM MgSO
4
, pH 6.5, to a lipid concentration
of 20 mg·ml-1. These proteoliposomes were frozen in 0.5 ml aliquots and stored in
liquid nitrogen. For use in transport experiments, proteoliposomes were 5 times froze-
thawn in liquid nitrogen and extruded 11 times through a 200 nm lter. Extruded
proteoliposomes were collected by centrifugation (TFT65.38 rotor, 140,000×g, 4 °C, 30
minutes), resuspended in 50 mM KP
i
, 2 mM MgSO
4
, pH 6.5, to a lipid concentration
of 80 mg·ml-1, stored on ice and used within 24 hours.
Testing membrane integrity of liposomes The uorophotospectrometer (Shimadzu
RF-5301) was set to excitation wavelength 482 nm and emission wavelength 520 nm
using 1.5 and 3 nm slit width, respectively. Prepared liposomes (15 µl), loaded with
100 mM KP
i
, 2 mM MgSO
4
, pH 6.5, were resuspended in 2 ml 100 mM N -Methyl-
D-glucamine(NMDG)-HEPES, 2 mM MgSO
4
, pH 7, and constantly stirred in a 2 ml
quartz cuvette. After start of recording the emission, 3,3'-diethyloxacarbocyanine iodide
(DiOC
2
(3)) was added to a concentration of 5 µM. When a stable uorescent signal
was obtained, valinomycin was added to a nal concentration of 1 µM. The increase
of DIOC
2
(3) was traced until a plateau was reached and KCl was added to a nal
concentration of 200 mM.
Transport experiments with reconstituted AcrB using uorescent substrates For
the uorescent AcrB substrates N -phenylnaphthylamine (NPN) and Hoechst 33342 set-
tings at the uorophotospectrometer (Shimadzu RF-5301) were set to excitation wave-
length 355 nm, emission wavelength 420 nm and 355 nm, 457 nm, respectively. Slit
width for excitation and emission was set to 5 nm. Prepared liposomes (1550 µl)
were resuspended in KP
i
buers of lower pH to establish a ∆pH and in NaP
i
buers
of lower pH to generate ∆pH and ∆Ψ after the addition of valinomycin. The sample
was constantly stirred in a quartz cuvette during measurements. The AcrB substrates
NPN and Hoechst 33342 were added to concentrations of 0.251 µM and 0.050.25 µM,
respectively.
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5.1 Allostery and cooperativity in multimeric assemblies
Allosteric regulation is a mechanism to control the activity of a catalytic protein (e. g. en-
zyme, carrier or pump) without altering this protein's availability. The concept of al-
lostery envisions binding of eector molecules to the allosteric site (which is a site other
than the primary binding site) of the catalytic protein in order to modulate its activity
by structural conversions. These modulations may be positive or negative, in- or de-
creasing the activity, respectively. Typically, allosteric regulated proteins share certain
attributes. They often consist of two (or more) identical subunits and the holoenzyme
exhibits a symmetric architecture. Furthermore, these proteins commonly adopt two
conformations, referred to as the T (tense) and the R (relaxed) state, where substrate
anity generally is higher in the R state. Stimulatory and inhibitory allosteric eectors
stabilize the R and T state, respectively, modulating the rate of the reaction. Coopera-
tivity is a self-regulatory eect emerging from two or multiple substrate binding sites in
which binding of a ligand to one of the binding sites alters the anity of the ligands to
the other binding sites by structural changes. Cooperativity can again have stimulatory
or inhibitory eects and is typically observed in multimeric assemblies.
The MWC (Monod/Wyman/Changeux) or symmetry model describes allosteric changes
in homomultimeric proteins to adapt substrate anity [151]. The best known implemen-
tation of this model is the description of cooperative binding of oxygen to hemoglobin.
Hemoglobin is a pseudosymmetric tetramer, composed of 2 α and 2 β subunits, each
harboring a heme prosthetic group involved in the binding of one molecule of oxygen.
Each of the four subunits can adopt two dierent conformations: the T (tight) state
(conformation of deoxyhemoglobin) and the R (relaxed) state (conformation of oxyhe-
moglobin). In the symmetry model, binding of oxygen to one of the protomers in T
conformation enhances the subsequent T to R transition of all four subunits and as a
result, increases oxygen anity of the ligand-free monomers. The cooperativity mode
is explained by the tight packing of the subunits and the spontaneous leveraging of
conformational changes to the adjacent subunits. The MWC model suggests symmetric
distribution of the conformational states in a way that all subunits adopt either the T
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or R conformation, independent of the oxygenated state of the subunits. An alterna-
tive model to the MWC model was presented by Koshland/Némethy/Filmer [152], also
known as the sequential or KNF model. This model anticipates a sequential confor-
mational conversion of single subunits upon substrate binding and features cooperative
interactions of adjacent subunits, resulting in a change of substrate anity. Applied
to oxygen binding of hemoglobin, this model starts with deoxyhemoglobin in which all
four subunits are present in the T state. Binding of oxygen to one of the subunits causes
transition to the R conformation of the oxygen binding subunit and simultaneous in-
crease of oxygen anity of the adjacent subunit. Binding of oxygen continues until all
four subunits adopted the R conformation and the hemoglobin is fully oxygenated. The
featured cooperativity can be positive (as observed in hemoglobin) as well as negative.
Concerning trimeric RND eux pumps, both models are still up for sale. Whereas the
proposed functional rotation model for AcrB is much along what would be described
by the KNF model, the MWC model may be possibly used to describe the mechanism
of CusA, a copper and silver ion RND transporter in Escherichia coli. Latest crystal
structure data indicate the presence of two dierent conformations, depending on the
presence of its substrate, for example copper ions [45]. In contrast to the asymmetric
crystal structures of AcrB [7375] the structures of CusA reveal symmetric trimers,
where one conformation is observed in the absence and one conformation in the presence
of copper ions. Experimental support for the KNF model type of allostery in the case
of AcrB was provided by whole cell eux kinetics. The group of Nikaido developed
in vivo assays to determine eux kinetics in E. coli cell mediated by AcrAB-TolC.
Investigated substrates were cephalosporins [153] and penicillins [154]. These studies
showed that eux kinetics of most tested substrates revealed a sigmoidal rather than a
Michaelis-Menten type saturation curve. The observation of sigmoidal curves is a strong
indication for a positive cooperative binding to AcrB, since it describes an increase of
substrate anity with increasing substrate concentration. Calculated Hill coecients
(varying between 1.9 and 4.7) provide indication for rather strong cooperative kinetics
due to more than one binding site for substrates within the AcrB trimer.
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Molecular basis of allostery and cooperativity and putative determinants for AcrB
In hemoglobin, the molecular mechanism of cooperativity is well studied. Human
hemoglobin is comprised of two identical α-chains (α1 and α2) and two identical β-
chains (β1 and β2). Association of molecular oxygen to the heme iron causes a struc-
tural change and congurational shift (undoming) of the porphyrinring. These rather
subtle structural alterations are leveraged via a covalently attached histidine side chain
(His F8) to an adjacent helix (helix F) which is coupled to changes at the α1 - β2
and α2 - β1 interfaces where disruption of hydrogen bonds and formation of new ones
occurs. As a consequence, the subunits have a dierent set of hydrogen bonding pattern
at the interface region in the T or R state. Since the R-state has a higher anity for
oxygen, the allosteric conformational change caused by the binding of oxygen to the
neighbouring monomer results in the observed cooperative binding kinetics [155].
Another case of enzymatic allostery is displayed by the aspartate transcarbamoylase
(ATCase) of E. coli, which catalyzes the generation of N -carbamoyl aspartate from
carbamoyl phosphate and aspartate. This multimeric enzyme complex exhibits cooper-
ative kinetics due to the binding of both of it substrates and furthermore is allosterically
regulated e. g. stimulatory by ATP and inhibitory by the downstream product cytidine
triphosphate (CTP). The latter feedback mechanism tightly regulates the production of
CTP in the bacterial cell. The ACTase is comprised of six catalytic subunits and six reg-
ulatory subunits. The catalytic subunits are arranged in two trimers that congruently
face each other. Three dimers of the regulatory subunits bind to the catalytic assembly
in a threefold symmetry. The transition from T to R state features a conformation in
which the two catalytic trimers move together and rotate to form the catalytic active
form of the ATCase. Similar to the situation in hemoglobin, quaternary alterations are
crucial for the allosteric regulation [155].
Yet another example of allostery is reported for the glycogen phosphorylase, which cat-
alyzes the degradation of glycogen. It is a homodimeric enzyme and the active site is
occluded in the T and accessible in the R state. The conformational shift from T to
R is promoted by phosphorylase kinase which results in changes in the tertiary and
ultimately quarternary structure of the enzyme. Crucial for the quarternary alterations
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is the tilting of the tower helices that connect the two monomers. The tower helices,
one from each subunit, are oriented antiparallel at the interface of the monomers. In the
transition from the T to R conformation, they move relatively to each other. Like ob-
served in the hemoglobin, this results in a change of interaction prole (hydrogen bonds,
ionic interactions) of the side chains located on the helices. The glycogen phosphory-
lase is allosterically inhibited by downstream products of glycogen breakdown (glucose,
adenosine triphosphate, glucose-6-phosphate) stabilizing the T state [156].
As the examples described above demonstrate, cooperativity may be mediated by hydro-
gen bonds or ionic interactions at the interfaces of monomers. Changes in the tertiary
structure (conformation) of the monomers may shift, break or establish single or a series
of hydrogen bonds or salt bridges that transmit conformational information to the adja-
cent monomer. On the basis of the asymmetric model of AcrB (pdb ID: 2GIF) by Seeger
et al. [74] hydrogen bonding and salt bridges at the interfaces of the three monomers
were analyzed using the web based tool PISA (Protein interfaces, surfaces and assem-
blies service PISA at European Bioinformatics Institute (http://www.ebi.ac.uk/msd-
srv/prot_int/pistart.html), authored by E. Krissinel and K. Henrick [157]). Numerous
hydrogen bonds and a few salt bridges were found to be established at the interfaces of
the AcrB monomers (Tables 5.1, 5.2 and 5.3).
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Table 5.1: Hydrogen bonds observed at the interfaces between L, T and O of the asymmetric AcrB based on the high resolution model (pdb ID:
2GIF). Only dynamic bonds that are present in one or two of the three interfaces are specied. Residue names and numbers, distances and involved
atom (e. g. [OD2]) are indicated.
Residue 1 Distance (Å) Residue 2 Interface Residue 1 Distance (Å) Residue 2 Interface
PHE 11 [N] 3.80, 3.19 GLU 893 [OE1] OL, OT ASN 109 [OD1] 3.27 VAL 129 [N] OL
PHE 11 [N] 3.68 GLU 893 [OE2] OL LYS 110 [NZ] 2.82 VAL 129 [O] TL
TYR 49 [OH] 2.67 ARG 239 [NH2] OT LYS 110 [NZ] 2.94 ASP 174 [OD1] OT
GLY 51 [O ] 3.56, 3.31 ALA 216 [N] TL, OL ASN 161 [ND2] 3.71 GLN 687 [O] TL
GLY 51 [O] 2.98, 2.81 GLY 217 [N] TL, OL ARG 168 [NH1] 3.21 ASN 820 [O] OL
THR 56 [OG1] 2.96, 2.77 GLN 213 [NE2] TL, OL ARG 168 [NH2] 2.69 ASN 820 [O] TL
ASP 59 [O] 3.39, 2.53 ARG 239 [NH1] TL, OL ARG 168 [NH2] 3.84 GLY 821 [O] OT
ASP 59 [O] 3.81 VAL 768 [N] OT ALA 209 [O] 3.21 GLN 733[ NE2] OL
THR 60 [OG1] 3.84 ARG 239 [NH2] TL GLN 218 [NE2] 3.82 GLN 622 [OE1] OL
GLN 63 [OE1] 2.78, 3.05 VAL 768 [N] TL, OL THR 222 [N] 3.24, 3.72 GLN 622 [OE1] OL, OT
GLU 66 [O] 3.06 ARG 168 [NH2] OL THR 222 [OG1] 2.60 TYR 275[O] TL
GLN 67 [OE1] 3.13 ARG 767 [NH2] OT THR 222 [OG1] 3.64 GLN 584 [OE1] TL
MET 69 [O] 2.75 ARG 168 [NE] OL THR 222 [OG1] 3.32 ASP 276 [N] OL
ASN 70 [OD1] 3.73 VAL 175 [N] OT THR 222 [OG1] 2.58 ASP 276 [OD1] OT
GLY 71 [N] 3.25, 3.36 SER 167 [O] TL, OL GLN 228 [N] 3.85 GLU 585 [OE1] OT
ASP 73 [OD2] 2.76, 2.65 LYS 131 [NZ] TL, OL GLN 228 [O] 3.25 THR 583 [OG1] OT
ASN 74 [N] 2.67 SER 170 [OG] TL LEU 230 [N] 3.81 THR 583 [OG1] TL
ASN 74 [OD1] 3.75 SER 170 [OG] TL ASN 231 [ND2] 3.07 GLN 622 [OE1] OL
ASP 101 [O] 3.41 ASN 109[ ND2] OT GLN 237 [NE2] 3.77 ASN 747 [OD1] OL
ASP 101 [OD1] 3.30 GLN 106 [NE2] TL GLN 237 [OE1] 3.78 ASN 747 [ND2] TL
ASP 101 [OD2] 2.77 GLN 106 [NE2] OT THR 238 [OG1] 3.86, 3.44 LYS 728 [NZ] OL, OT
GLN 108 [NE2] 3.65 ASN 109 [OD1] OT LEU 250 [O] 3.65 GLN 737 [NE2] TL
GLN 108 [NE2] 3.13 ASN 109 [O] OT ARG 259 [NE] 2.99 GLU 734 [OE2] OL
GLN 108 [OE1] 3.87 GLN 112 [NE2] TL ARG 259 [NH1] 2.78 GLU 734 [OE2] TL
GLN 108 [OE1] 3.89 LEU 113 [N] OT
1
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A total number of 49 dynamic hydrogen bonds were found at the investigated interfaces.
These interactions, only present in one or two of the three surfaces, may be the struc-
tural basis for a potential cooperative mechanism. Eleven hydrogen bonds were found
to be specic for the OL interface and 14 bonds for the OT and TL interface, each.
The number of hydrogen bonds found in two out of three interfaces was signicantly
smaller: three and seven for OL, OT and TL, OL, respectively. Interestingly, there are
no common hydrogen interactions observed in the TL, OT interfaces. Out of the 63
reported hydrogen bonds, 14 were found in all three interfaces. These static interac-
tions are shown in Table 5.2. Remarkably, the majority (12) of these static hydrogen
bond interactions involve the intermonomeric loop (Loop) and the DC subdomain of
the TolC docking domain or the PC1 subdomain. The occurrence of the static hydrogen
bonds in all three interfaces makes them rather unlikely candidates for participation in
cooperativity mechanisms; on the other hand the observed interactions may emphasize
the loop structure as a determining structure for the trimeric assembly of AcrB. The
trimer might be stabilized by these static intermonomer interactions (Chapter 2).
Additionally to the static hydrogen bonds associated with the Loop, there is an in-
teraction involving the PN1 and the TolC docking domain and one observed in the
transmembrane domain (TM1-TM8).
In addition to the hydrogen interactions in the three intermonomeric interfaces, also
ionic interactions were analyzed. A total number of 10 individual ionic interactions
(salt bridges) could be observed in ve pairs of residues (Arg 8 - Glu 893, Asp 73 - Lys
131, Lys 110 - Glu 130, Lys 110 - Asp 174, Arg 259 - Glu 734) (Table 5.3).
Ionic interactions could be observed in all three interfaces and ve, two and one in-
teractions were found to be specic for the OL, TL and OT interface, respectively.
Interestingly, the ionic interaction pairs Asp 73 - Lys 131 and Arg 259 - Glu 734 were
observed at the interfaces of TL (T monomer and L monomer) and OL (O monomer
and L monomer), whereas these interaction were not found in the OT interface. These
specic salt bridges are established between the PN1 subdomains (Asp 73 - Lys 131)
and between the DN subdomain and the neighboring DC subdomain (Arg 259 - Glu
734), respectively. Lysine 131 was found to interact with aspartate 73 at the TL (2
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Table 5.2: Static hydrogen bonds of the interfaces of the L, T and O monomer of AcrB (based
on the high resolution structure pdb ID: 2GIF) and involved domains. TM: transmembrane
helix, docking domain: TolC docking domain, Loop: intermonomeric loop of AcrB.
Residue 1 Distance (Å) Residue 2 Domains
ILE 10 [N] 3.06 GLU 893 [OE1] TM1-TM8
GLN 63 [NE2] 3.52 GLY 766 [O] PN1-docking domain
GLN 218 [N] 3.56 TRP 754 [O] Loop-DC
GLY 220 [N] 3.51 ARG 780 [O] Loop-DC
GLY 220 [N] 3.08 MET 781 [O] Loop-DC
GLY 221 [O] 3.00 ARG 780 [NH1] Loop-DC
PRO 223 [O] 2.59 ARG 780 [NH2] Loop-DC
GLY 227 [N] 2.62 GLU 585 [OE1] Loop-PC1
GLN 228 [NE2] 3.41 MET 781 [O] Loop-DC
ASN 231 [N] 3.25 GLY 581 [O] Loop-PC1
SER 233 [O] 2.87 PHE 727 [N] Loop-DC
ILE 235 [O] 2.71 ILE 729 [N] Loop-DC
ILE 235 [N] 2.76 PHE 727 [O] Loop-DC
ALA 236 [O] 2.68 LYS 728 [NZ] Loop-DC
interactions) and OL (1 interaction) interface whereas at the OT interface this specic
interaction was absent (Figure 5.1).
Notably, no ionic interactions are observed which are present in all three interfaces and
only one interaction is present at the interface OT (Table 5.3).
The characterized dynamic hydrogen bonds as well as the salt bridges, may be involved
in a cooperative mechanism of the AcrB trimer. Mutagenesis studies to disrupt specic
interactions may reveal their inuence on the activity of AcrB.
Cooperative eect of other known membrane transporters
Cooperative substrate binding eects in membrane transporters is a well described phe-
nomenon. In the monomeric eukayotic multidrug exporter P-glycoprotein (P-gp or
MDR1) it was found that two substrate binding sites exhibit positive cooperativity
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Figure 5.1: Top view on the PN1 subdomains of the loose (L, blue), tight (T, yellow) and
open (O, red) monomers of AcrB (pdb ID: 2GIF) in cartoon representation. In the center, the
three pore helices of the PN1 subdomains are visible. Aspartate 73 and lysine 131 that are
involved in salt bridging are shown as sticks and the salt bridges (with the distances in Å) are
indicated by green dotted lines. The salt bridge at the interface of TL (lower left) and OL (top)
is not present at the OT interface (lower right).
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Table 5.3: Salt bridges of the interfaces between L, T and O of the asymmetric AcrB based
on the high resolution model (pdb ID: 2GIF). Residue names and numbers, distances, involved
atom (e. g. [NH1]) and interfaces are indicated.
Residue 1 Distance (Å) Residue 2 Interface
ARG 8 [NH1] 3.96 GLU 893 [OE2] OL
ASP 73 [OD1] 3.35 LYS 131 [NZ] TL
ASP 73 [OD2] 2.76, 2.65 LYS 131 [NZ] TL, OL
LYS 110 [NZ] 2.88 GLU 130 [OE1] OL
LYS 110 [NZ] 3.43 GLU 130 [OE2] OL
LYS 110 [NZ] 2.94 ASP 174 [OD1] OT
ARG 259 [NE] 3.93, 2.99 GLU 734 [OE2] TL, OL
ARG 259 [NH1] 2.78 GLU 734 [OE2] TL
ARG 259 [NE] 3.31 GLU 734 [OE1] OL
ARG 259 [NH2] 3.22 GLU 734 [OE2] OL
[158]. In the bacterial LeuT leucine transporter, cooperativity between leucine bind-
ing and sodium ion binding has been observed in all-atom free-energy perturbation
(FEP)/molecular dynamics (MD) simulations using a high resolution (1.65 Å) model
[159]. The sodium dependent LeuT harbors a leucine binding site as well as two distinct
sodium binding sites. FEP/MD simulations revealed a strong cooperativity between
leucine binding and sodium coordination in the adjacent sodium binding site (NA1)
whereas binding of sodium to the second binding site (NA2) seems non-cooperative.
The structural basis for this interaction arises from the fact that the carboxyl group of
the bound leucine is involved in the coordination of the sodium in NA1 [160].
Also in the sodium dependent citrate transporter CitS of Klebsiella pneumonia coop-
erativity of binding of the two sodium ions was demonstrated [161, 162]. However,
the structural basis for this mechanism remains occluded due to the lack of a crystal
structure for CitS.
Recently, the structural basis for cooperativity in the sodium-independent carnitine/bu-
tyrobetaine antiporter CaiT from Proteus mirabilis was revealed using high resolution
structures. Binding experiments exhibited a Hill coecient greater than one, thus
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suggesting cooperativity in substrate binding. It could be shown that binding of buty-
robetaine causes structural rearrangements that open the second binding site [163].
A dierent mechanism of cooperativity is observed for the trimeric glycine betaine
(N,N,N -trimethylglycine) symporter BetP from Corynebacterium glutamicum that im-
ports the osmolyte betaine from the environment to escape osmotic stress. In a re-
constituted system the C-terminal domain was shown to be crucial for the regulation
via sensing of high cytosolic K
+
concentrations in the case of osmotic stress [164].
BetP was shown to be a trimer in membranes by 2D crystallography and electron cryo-
microscopy [165]. Recent high resolution data revealed the presence of a trimer with
non-crystallographic symmetry (NCS) [166]. The crystal structure further indicates
the role of the C-terminal helix as an intermonomeric activator that exhibits protein-
protein interactions [167] between the C-terminal domain and residues of the neigh-
boring monomer. At the interface of the B and the C monomer, a salt bridge between
arginine 565 on the C-terminal domain of the C monomer and aspartate 131 on the loop
structure loop 2 from the B monomer is observed (Figure 5.2). Glutamate 132 on loop
2, on its part, is also involved in a salt bridge interaction with arginine 390 located on
loop 8. This interaction network may establish a link between the C-terminal helix and
loop 8, which is gating the substrate pathway, via loop 2. Changes of orientation in
the regulatory C-terminal helix upon stimulatory osmotic alterations are postulated to
induce conformational changes that would unblock the pathway [167]. Via this mecha-
nism the C-terminal domain of BetP is supposed to activate and deactivate the adjacent
monomer by pushing and pulling the gating loop 8 by way of this salt bridge network.
Activation of BetP, therefore, seems to be dependent on its trimeric state. In contrast,
transport experiments [168] clearly indicated that transport itself is non-cooperative,
suggesting independent action of each monomer in the trimeric assembly.
5.2 AcrB: Cooperativity and the binding change mechanism
The functional assembly of the AcrAB-TolC drug eux pump in E. coli appears to be
controlled by the concentration of the three components itself in the cell. Specically, it
appears that AcrA concentration inside the periplasm is key to modulating the activity
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Figure 5.2: Close up view of the salt bridge network of the glycine betaine transporter BetP
from Corynebacterium glutamicum (pdb ID: 2WIT). The loop structures loop 2 and loop 8
of the B monomer (blue) are shown in orange and magenta, respectively. The ionic interactions
of the arginine 565 at the C-terminal domain of the C monomer (green helix) and the aspartate
131 (loop 2) and glutamate 132 (loop 2) and arginine 390 (loop 8) are shown in yellow (distance
in Å). These salt bridge interactions may leverage changes in the orientation of the C-terminal
helix to the substrate pathway via loop 2 and loop 8. These changes are suggested to happen
upon alteration in the osmolarity of the cell and promote transport activity in the B monomer.
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of this specic RND system by its ability to recruit TolC (and AcrB) [169]. Drug trans-
port by the AcrB trimer has been shown to be a highly cooperative process [153, 154].
The basis for this cooperativity lies in the functional rotation mechanism with the much
emphasized analogy to the binding change mechanism as originally proposed by Boyer
for the enzyme ATP synthase [83, 170, 171].Trimeric AcrB has been directly observed
in a symmetric (closely resembling a LLL conguration) state in initial [70, 72, 125] and
in LTO conguration in recent crystal structures [7375]. Whereas the LTO state of the
trimer is strongly suggested to represent a physiological state of AcrB, the LLL state
is believed to display an inactive form i. e. in the absence of substrates [86, 172]. This
postulate was recently substantiated by molecular dynamics (MD) simulations of the
porter domains of the AcrB trimer by Yao et al. [173]. Interpretation of the simulation
data suggests that the binding of substrate to the T monomer stabilizes the LTO state,
whereas dissociation of the substrate may sustain a LLL state. The simulations were
conducted with one AcrB substrate present, whereas in the physiological situation, more
than one drug molecules might be binding to AcrB. The understanding of the possible
conformations of the AcrB trimer led to a schematic representation of the functional
rotation mechanism that illustrates a conformational cycling and integrates possible in-
termediate steps found in crystal structures and derived from crosslinking data (Figure
5.3) [86].
Additionally, a TTT conguration has been observed in the crystal structures of two
individual binding pocket variants of AcrB (Eicher et al. , unpublished; Cha et al. ,
unpublished). Furthermore, low resolution crystallographic data of one of the crosslink
variants (Chapter 3) indicates a TTT conguration. In contrast to the binding pocket
variants, this variant did not show altered substrate specicity and MIC data suggest
its transport activity resembles that of the wildtype. So, theoretically, a TTT trimer
may also be a possible intermediate step in the wildtype AcrB. In contrast to that
assumption, a TTT state could not be observed in the MD simulations [173]. This,
however, may be attributed to the fact that single substrate simulations were performed.
Nevertheless, recent crystallographic studies on the AcrB homolog CusA, a metal ion
transporter of E. coli, revealed two dierent conformations, one of which with copper
ions bound to all three monomers of CusA [45]. The conformations of the apo and
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Figure 5.3: Schematic representation of the functional rotation of the homotrimeric multidrug
eux pump AcrB. Monomers adopting the conformations, loose (L), tight (T) and open (O)
are colored blue, yellow and red, respectively. The horizontal succession may represent the
transport cycle in AcrB, whereas the states TTT and LLL (and LLT) may represent states of
high and low substrate concentrations, respectively. Evidence for the existence of individual
states by crystallographic (X), molecular dynamics (MD) and cross-link (CL) experiments are
indicated. Adapted from Pos [86] with permission.
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copper bound CusA closely resemble OOO and TTT states of AcrB, respectively. In the
T state, substrates (e. g. 9-bromo-minocyclin, doxorubicin or minocyclin) were shown
to bind to the binding pocket of AcrB ([73] and Pos et al. , unpublished).
Crosslink studies with AcrB double cysteine variants also revealed evidence for the
existence of trimer congurations, other than LLL, LTO and TTT. Due to crosslink
quantication in the cysteine variants, it has been shown that more than one monomer
may adopt the L or T conformation [77]. This would allow the trimer to (hypotheti-
cally) form LLT, TTO and TTL. These trimer states have not been observed in crystal
structures of AcrB so far. It might be possible that they represent temporary trimer
states that are part of the actual rotation mechanism. In contrast to the LLL, TTT or
LTO trimers, these may be utmost transient transitional geometries. Some indication
for the occurrence of these transitional states was provided by thermodynamic analysis
of the AcrB trimer porter domains by Yao et al. [173]. Using calculated inter-protomer
interactions of the AcrB trimer, probabilities for dierent states of the trimer were ob-
tained by equilibrium thermodynamic simulations. Whereas the probability of TTL
and LLT were found to be modest in simulations with bound substrate, evidence for
TTL could only be detected in the simulations optimized for the asymmetric state. In-
terestingly, an additional state of LLO could be observed in these simulations without
bound substrate.
In the postulated transport cycle (Figure 5.3), the LLO conguration has not been con-
sidered so far. However, dynamic simulations indicated that drug transport in only one
monomer may be completed without the necessity of the other monomers to undergo
full functional rotation. Consequently, the transport scheme may theoretically be ex-
tended in a way that describes only one monomer to undergo conformational cycling
in the sense of an LLL - LLT - LLO transition. However, this consideration is based
on single substrate simulations and contradicts the bi-site activation postulated for
AcrB [86] on basis of the analogy to this eect observed in the F
1
F
O
-ATPase. Never-
theless, Yao et al. state that . . . the complete conformational changes in the trimer
are necessary for the next cycle [173]. In theory this fact may suggest another model
for the transport cycle where the monomers not necessary follow concerted change of
conformation. In contrast to the proposed model, the monomers may independently
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cycle through the conformations L, T and O to a certain extent. The results from the
dynamic simulations clearly indicate successful drug export via the exit leading to the
TolC docking domain although only one or two monomers changed their conformation.
This idea envisages a big variety of dierent trimer states that come along with the
partially independent rotation of the monomers. All possible combinations of the three
conformations may be possible with the exception of two neighboring O conformers.
These O conformers would result in a steric clash of porter subdomains [174]. However,
the suggestion of largely independent conformational cycling of the monomers appears
to be in contrast to the ndings of Takatsuka et al. [80], where it was shown that the
inactivation of one of the monomers leads to an inactivation of the entire trimer.
Additionally, one may think of an equilibrium between the L and T conformation since
these conformers are relatively similar to each other. In fact single monomer simula-
tions suggest that transition frequencies between L and T conformations are signi-
cantly higher than to and from the O conformation [173]. This mechanism may allow
substances allow entering and binding, in case they are substrates, or being released
from AcrB when they do not bind to the binding pocket. Bound substrate, however,
may stabilize the T state and subsequently allow protonation and transition to the O
monomer. This speculative alternative model sustains the explanation of LLL trimers
due to low substrate concentrations, but cannot explain the extraordinary stability of
the LTO state, as demonstrated by numerous crystal structures of AcrB representing
LTO. However, it explains the existence of other observed asymmetric congurations
other than LTO (Figure 5.3).
Crystal structures from the covalently linked AcrB, carrying one non-functional monomer
(D407N) from Takatsuka et al. [80] are highly anticipated and may reveal new insights
on the conformational rotation of AcrB. According to the proposed mechanism, the
change from T to O is energy dependent. In the structure of the covalent AcrB, the
non-functional monomer is expected to adopt the L or T conformation, however not
the O conformation. It can only be speculated which conformations the neighboring
monomers adopt or what the conformational state of a covalently linked trimer carrying
two non-functional monomers might be.
As a synthesis of the ndings discussed above, the transport mechanism of AcrB may
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alternatively be described as a quasi two state model. According to the alternate access
model of Jardetzky, the mechanism may be explained by an inside facing and an outside
facing conformation. The open (O) conformation would constitute the outside facing
conformation and the loose (L) and tight (T) conformations display two variations of
inward accessible conformation in equilibrium.
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6 Conclusions and outlook
AcrB is the most intensively studied RND protein and probably one of the best charac-
terized bacterial multidrug eux pumps in Escherichia coli, both structural and func-
tional. Especially structural information about AcrB is abundant. At the present time
there are 26 crystal structure deposits in the Protein Data Bank (www.pdb.org). Some
of the structures were co-crystallized with ligands, e. g. substrates, DARPin binders,
ions and peptides and most structures represent AcrB as a symmetric trimer, whereas
the more recent structures reveal an asymmetric conguration of the trimer. The few
kinetic data on AcrB are limited to observations from in vivo experiments. The lack of
in vitro transport and substrate binding data is attributed to the lack of a suitable and
successful transport assay of membrane vesicles containing AcrB or liposomes harboring
reconstituted AcrB.
Crystallization of crosslink variants of AcrB
The presented structures from AcrB crosslink variants (Chapter 3) revealed insights
into the conformational cycling of AcrB. It could be shown that the PC2 subdomain
may move independently from the PN1 subdomain during conformational cycling and
interestingly the intermediate conformation of PC2 still allows DARPin binding. Fur-
thermore, there is indication of an all tight (TTT) conguration of one of the crosslink
variants in low resolution data. This TTT state of AcrB could only be observed in
binding pocket variants so far. Improvement of these putative TTT crystals and the
up to now non-diracting loop-PC1 crystals may lead to additional insights into the
functional rotation process. Crystal microseeding and co-crystallization with dierent
substrates may lead to better crystals and higher resolution. Furthermore, the crystal-
lization of the non-functional mutants, carrying deteriorating amino acid substitution
in the proton translocation pathway, may display novel or additional conformational
states and provide deeper understanding of the functional rotation of AcrB. Especially,
the crystallization of the covalently linked trimer containing one or two non-functional
monomers of AcrB constructed by Takatsuka et al. [80] would be of great interest in
view of the conformational cycling.
116
6 Conclusions and outlook
Reconstitution of AcrB into proteoliposomes
The functional reconstitution of AcrB is imperative to establish a suitable method to
investigate substrate binding and transport parameters of AcrB. Measurements done
in bacteria and membrane vesicles from bacterial cells, theoretically, may be falsied
by the presence of other endogenous multidrug eux systems with overlapping sub-
strate specicities. Kinetic parameters have already been obtained from intact cells
expressing AcrB by indirect measurements [153, 154]. These studies provide a good
approximation of the transport kinetics of β-lactams but measurements in a reconsti-
tuted system would provide access to data for other substrate classes as well. Initial
experiments of reconstituting AcrB were performed in this thesis (Chapter 4). Although
incorporation of AcrB into liposomes after the reconstitution process has been shown,
experiments with electrochemical proton gradients and dierent AcrB substrates did
not succeed demonstrating substrate transport across the membrane via uorescence
tracing. These ndings may conrm in vivo experiments [142] showing that only the
holo complex (AcrAB-TolC) acts as a functional drug export machinery. Despite the
fact that AcrB is the energy conversion module and the substrate determining factor
within the tripartite complex, in a reconstitute system it may require structural assists
of docked AcrA and TolC to perform drug transport. To circumvent this problem,
one could envisage a reconstituted system, addition of AcrA and soluble TolC may
promote the formation of the tripartite system in vitro and give rise to AcrB activity.
Furthermore, the present experimental setup may be inapplicable for transport studies
with lipophilic AcrB substrates. These substrates were thought to be relocated from
the liposome membranes to the aqueous outside medium and indicated by changes in
uorescence. It is imaginable that these compounds readily reinsert again into the
membrane after being expelled. Especially when the partitioning kinetics outperforms
AcrB's transport rate, the detection of transport would be futile. On the contrary,
transport could be detected in equal experiments with primary (LmrA [175]) and also
secondary transporters (NorA [149]). It is imaginable, that these transporters exhibit
higher transport rates than AcrB and thus exceed repartitioning of the substrate into the
membranes which resulted in a measureable net export of the substrate. One potential
approach to avoid this situation is the use of dierent populations of vesicles/liposomes,
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similar to the experiments performed by Zgurskaya et al. [142]. One may use two dier-
ent liposome species each containing reconstituted AcrB or TolC in orientations so that
they may, in the presence of soluble AcrA, spontaneously form a complex resembling
that in bacterial cells. Using such an experimental setup, preloaded substrates may
be transported from AcrB containing liposomes into TolC liposomes. Target (TolC)
liposomes needed to be separated to measure substrate transport.
Small amounts of soluble monomeric β-barrel less TolC protein could be puried. In
order to use this TolC variant in transport experiments it is crucial to express and
purify it as stable trimeric assemblies. Revised construction in accordance to the work
of Kim et al. [145] may result in a soluble trimeric TolC variant lacking the β-barrel
domain. This variant may be useful in transport experiments in a reconstituted system
with AcrB and AcrA. Furthermore, complex formation with puried, solubilized AcrB,
AcrA and the TolC variant may be studied in vitro. The ultimate goal will be the co-
crystallization of the individually puried compounds AcrA, AcrB and the TolC variant
to understand the complex function of this tripartite eux machinery (Figure 6.1).
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Figure 6.1: Schematic side view of the AcrAB-TolC assembly of E. coli. The inner membrane
pump AcrB (green) is inserted in the inner membrane and the outer membrane protein TolC
(red) is embedded in the outer membrane. In the periplasm the complex is stabilized by the
membrane fusion protein AcrA (blue). This model based on crosslink experiments shows a 1:1:1
stoichiometry of the three components [94]. The model coordinate le is a courtesy of Martyn
Symmons.
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